Brazil Diagnostic Labs Market: Forecast To 2028 - Covid-19 Impact and Country Analysis

Brazil Diagnostic Labs Market
Forecast to 2028 – Covid-19 Impact and Country Analysis

COVID-19 Impact & Country Analysis by Lab Type (Single/Independent Laboratories, Hospital-
Based Labs, Physician Office Labs, And Others), Testing Services [Physiological Function Testing
(ECG, Echo, X-ray, Endoscopy, CT, MRI, and Others), General and Clinical Testing, Esoteric Testing,
Specialized Testing, Non-invasive Prenatal Testing, COVID-19 Testing, and Others], Revenue
Source (Healthcare Plan Operators and Insurers, Out-of-Pocket, and Public System)
); End User (Hospitals, Ambulatory Surgery Centers, Pharmaceutical Companies, Others), and
Powered by TCPDF (www.tcpdf.org)
Downloaded by br_l6capital from 179.176.52.236 at 2023-03-14 17:22:12 UTC. EMIS. Unauthorized Distribution Prohibited.
TABLE OF CONTENTS
1. Introduction ................................................................................................................................................................ 20
1.1 Scope of the Study .............................................................................................................................................................................................. 20
1.2 The Insight Partners Research Report Guidance.............................................................................................................................................. 20
1.3 Market Segmentation ......................................................................................................................................................................................... 22
1.3.1 Diagnostic Labs Market – By Lab Type ............................................................................................................................................. 23
1.3.2 Diagnostic Labs Market – By Testing Services ................................................................................................................................. 23
1.3.3 Diagnostic Labs Market – By Revenue Source................................................................................................................................. 24
1.3.4 Diagnostic Labs Market – By Geography .......................................................................................................................................... 24
2. Diagnostic Labs Market – Key Takeaways .................................................................................................................... 25

3. Research Methodology ................................................................................................................................................ 27
3.1 Coverage.............................................................................................................................................................................................................. 29
3.2 Secondary Research ........................................................................................................................................................................................... 29
3.3 Primary Research ................................................................................................................................................................................................ 30
4. Diagnostic Labs Market – Market Landscape ............................................................................................................... 31

4.1 Overview .............................................................................................................................................................................................................. 31
4.2 PEST Analysis ...................................................................................................................................................................................................... 31
4.2.1 Brazil – PEST Analysis ........................................................................................................................................................................ 31
 www.theinsightpartners.com
2
Brazil Diagnostic Labs Market to 2028
5. Brazil Diagnostic Labs Market – Key Market Dynamics ................................................................................................. 32
5.1 Market Drivers..................................................................................................................................................................................................... 32
5.1.1 Rising Prevalence of Ageing-Related Diseases and Chronic Diseases ........................................................................................... 32
5.1.2 Growing Use of Point-of-Care Diagnostic Products ........................................................................................................................... 32
5.2 Market Restraints ............................................................................................................................................................................................... 33
5.2.1 Shortage of Skilled Healthcare Professionals and High Cost of Diagnostic Equipment ................................................................ 33
5.3 Market Opportunities .......................................................................................................................................................................................... 33
5.3.1 Increasing Number of Strategic Collaborations and Partnerships .................................................................................................. 33
5.3.2 For instance: ....................................................................................................................................................................................... 34
5.4 Future Trends ...................................................................................................................................................................................................... 35
5.4.1 Use of Artificial Intelligence (AI) and Analytics in Diagnostic Equipment ........................................................................................ 35
5.5 Impact Analysis ................................................................................................................................................................................................... 36
6. Diagnostic Labs Market – Brazil Analysis ..................................................................................................................... 37

6.1 Brazil Diagnostic Labs Market Revenue Forecasts and Analysis .................................................................................................................... 37
6.2 Brazil Diagnostic Labs Market, By Geography - Forecasts and Analysis ......................................................................................................... 38
6.3 List of Distributors in Brazil-Diagnostic Labs Market........................................................................................................................................ 38
6.4 Company Analysis ............................................................................................................................................................................................... 39
6.4.1 Market Positioning of Key Players ..................................................................................................................................................... 39
6.4.2 Comparative Company Analysis ........................................................................................................................................................ 40
3
6.4.3 Growth Strategy Analysis .................................................................................................................................................................... 41
6.4.4 Performance of Key Players ............................................................................................................................................................... 43
6.4.4.1 Dasa Labs ...................................................................................................................................................................... 43
6.4.4.2 Grupo Fleury .................................................................................................................................................................. 44
6.5 Market Share Analysis of Brazil Diagnostic Labs Market ................................................................................................................................. 45
7. Brazil Diagnostic Lab Market Revenue and Forecasts To 2028 – Lab Type..................................................................... 46
7.1 Overview .............................................................................................................................................................................................................. 46
7.2 Diagnostic Lab Market, by Lab Type 2022 & 2028 (%) ................................................................................................................................... 46
7.3 Hospital-based Labs ........................................................................................................................................................................................... 47
7.3.1 Overview .............................................................................................................................................................................................. 47
7.3.2 Hospital-based Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .................................................... 47
7.4 Single/Independent Laboratories ...................................................................................................................................................................... 48
7.4.1 Overview .............................................................................................................................................................................................. 48
7.4.2 Single/Independent Laboratories: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .............................. 48
7.5 Physician Office Labs (POL) ................................................................................................................................................................................ 49
7.5.1 Overview .............................................................................................................................................................................................. 49
7.5.2 Physician Office Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .................................................. 49
7.6 Others .................................................................................................................................................................................................................. 50
7.6.1 Overview .............................................................................................................................................................................................. 50
4
7.6.2 Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ........................................................................... 50
8. Brazil Diagnostic Lab Market Revenue and Forecasts to 2028– by Testing Services ...................................................... 51
8.1 Overview .............................................................................................................................................................................................................. 51
8.2 Diagnostic Lab Market Revenue Share, by Lab Type (2022 and 2028) ......................................................................................................... 51
8.3 Physiological Function Testing ........................................................................................................................................................................... 52
8.3.1 Overview .............................................................................................................................................................................................. 52
8.3.2 Physiological Function Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .................................... 52
8.3.3 Endoscopy Market .............................................................................................................................................................................. 53
8.3.3.1 Overview ......................................................................................................................................................................... 53
8.3.3.2 Endoscopy Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .................................. 53
8.3.4 X-Ray Market ....................................................................................................................................................................................... 54
8.3.4.1 Overview ......................................................................................................................................................................... 54
8.3.4.2 X-Ray Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ........................................... 54
8.3.5 CT Market ............................................................................................................................................................................................ 55
8.3.5.1 Overview ......................................................................................................................................................................... 55
8.3.5.2 CT Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ................................................ 55
8.3.6 ECG Market ......................................................................................................................................................................................... 56
8.3.6.1 Overview ......................................................................................................................................................................... 56
8.3.6.2 ECG Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ............................................. 56
5
8.3.7 MRI Market ......................................................................................................................................................................................... 57
8.3.7.1 Overview ......................................................................................................................................................................... 57
8.3.7.2 MRI Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ............................................. 57
8.3.8 Echo Market ........................................................................................................................................................................................ 58
8.3.8.1 Overview ......................................................................................................................................................................... 58
8.3.8.2 Echo Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ............................................ 58
8.3.9 Others .................................................................................................................................................................................................. 59
8.3.9.1 Overview ......................................................................................................................................................................... 59
8.3.9.2 Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ...................................................... 59
8.4 General and Clinical Testing .............................................................................................................................................................................. 60
8.4.1 Overview .............................................................................................................................................................................................. 60
8.4.2 General and Clinical Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ....................................... 60
8.5 COVID-19 Testing ................................................................................................................................................................................................ 61
8.5.1 Overview .............................................................................................................................................................................................. 61
8.5.2 COVID-19 Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ......................................................... 61
8.6 Esoteric Testing ................................................................................................................................................................................................... 62
8.6.1 Overview .............................................................................................................................................................................................. 62
8.6.2 Esoteric Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ........................................................... 62
8.7 Specialized Testing ............................................................................................................................................................................................. 63
6
8.7.1 Overview .............................................................................................................................................................................................. 63
8.7.2 Specialized Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ...................................................... 63
8.8 Noninvasive Prenatal Testing ............................................................................................................................................................................. 64
8.8.1 Overview .............................................................................................................................................................................................. 64
8.8.2 Non-Invasive Prenatal Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .................................... 64
8.9 Others .................................................................................................................................................................................................................. 65
8.9.1 Overview .............................................................................................................................................................................................. 65
8.9.2 Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ........................................................................... 65
9. Brazil Diagnostic Lab Market Revenue and Forecasts to 2028 – Revenue Source .......................................................... 66
9.1 Overview .............................................................................................................................................................................................................. 66
9.2 Diagnostic Lab Market Revenue Share, by Revenue Source (2022 and 2028) ............................................................................................ 66
9.3 Healthcare Plan Operators and Insurers ........................................................................................................................................................... 67
9.3.1 Overview .............................................................................................................................................................................................. 67
9.3.2 Healthcare Plan Operators and Insurers: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million).................... 67
9.4 Out-of-Pocket Arrangements .............................................................................................................................................................................. 68
9.4.1 Overview .............................................................................................................................................................................................. 68
9.4.2 Out-of-Pocket Arrangements: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ....................................... 68
9.5 Public System ...................................................................................................................................................................................................... 69
9.5.1 Overview .............................................................................................................................................................................................. 69
7
9.5.2 Public System: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)............................................................... 69
10. Brazil Diagnostic Lab Market Revenue and Forecasts to 2028 – Region Analysis .......................................................... 70
10.1 Brazil: Diagnostic Lab Market ............................................................................................................................................................................ 70
10.1.1 Overview .............................................................................................................................................................................................. 70
10.1.2 Brazil: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)............................................................................. 70
10.1.3 Brazil: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million) ........................................................................................ 71
10.1.4 Brazil: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million) ............................................................................ 72
10.1.5 Brazil: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD Million) ..................................................... 73
10.1.6 Brazil: Diagnostic Lab Market, by Revenue Source, 2019–2028 (USD Million) ............................................................................ 74
10.1.7 Brazil: Diagnostic Lab Market, by Cities, 2022 & 2028 (%) ............................................................................................................ 74
10.1.7.1 Sao Paulo: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ................................................ 75
10.1.7.1.1 Overview ................................................................................................................................................ 75
10.1.7.1.2 Sao Paulo: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ....................... 75
10.1.7.1.3 Sao Paulo: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million) ................................... 76
10.1.7.1.4 Sao Paulo: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million) ....................... 77
10.1.7.1.5 Sao Paulo: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD
Million) ................................................................................................................................................... 78
10.1.7.1.6 Sao Paulo: Diagnostic Lab Market, by Revenue Source, 2019–2028 (USD Million) ....................... 79
10.1.7.2 Rio de Janeiro: Diagnostic Lab Market– Revenue and Forecast to 2028 (USD Million) .......................................... 80
8
10.1.7.2.1 Overview ................................................................................................................................................ 80
10.1.7.2.2 Rio de Janeiro: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ................ 80
10.1.7.2.3 Rio de Janeiro: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million) ............................ 81
10.1.7.2.4 Rio de Janeiro: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million) ................ 82
10.1.7.2.5 Rio de Janeiro: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028
(USD Million).......................................................................................................................................... 83
10.1.7.2.6 Rio de Janeiro: Diagnostic Lab Market, by Revenue Source, 2019–2028 (USD Million) ................ 84
10.1.7.3 Salvador: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) .................................................. 85
10.1.7.3.1 Overview ................................................................................................................................................ 85
10.1.7.3.2 Salvador: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ......................... 85
10.1.7.3.3 Salvador: Diagnostic Lab Market, by Lab Type – 2019–2028 (USD Million) ................................... 86
10.1.7.3.4 Salvador: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million) ......................... 87
10.1.7.3.5 Salvador: Diagnostic Lab Market, by Physiological Function Testing – 2019–2028 (USD
Million) ................................................................................................................................................... 88
10.1.7.3.6 Salvador: Diagnostic Lab Market, by Revenue Source – 2019–2028 (USD Million)....................... 89
10.1.7.4 Brasilia: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) .................................................... 90
10.1.7.4.1 Overview ................................................................................................................................................ 90
10.1.7.4.2 Brasilia: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ............................ 90
10.1.7.4.3 Brasilia: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million)........................................ 91
10.1.7.4.4 Brasilia: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million) ........................... 92
9
10.1.7.4.5 Brasilia: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD
Million) ................................................................................................................................................... 93
10.1.7.4.6 Brasilia: Diagnostic Lab Market, Revenue Source, 2019–2028 (USD Million) ................................ 94
10.1.7.5 Other Cities: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ............................................. 95
10.1.7.5.1 Overview ................................................................................................................................................ 95
10.1.7.5.2 Other Cities: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ..................... 95
10.1.7.5.3 Other Cities: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million)................................. 96
10.1.7.5.4 Other Cities: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million) .................... 97
10.1.7.5.5 Other Cities: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028
(USD Million).......................................................................................................................................... 98
10.1.7.5.6 Other Cities: Diagnostic Lab Market, Revenue Source– 2019–2028 (USD Million) ....................... 99
11. Impact Of COVID-19 Pandemic on Brazil Diagnostic Lab Market ................................................................................. 100
11.1 Brazil: Impact Assessment of COVID-19 Pandemic ....................................................................................................................................... 100
12. Brazil Diagnostic Labs Market–Industry Landscape.................................................................................................... 102

12.1 Overview ........................................................................................................................................................................................................... 102
12.2 Growth Strategies Done by the Companies in the Market (%) ...................................................................................................................... 103
12.3 Organic Developments .................................................................................................................................................................................... 104
12.3.1 Overview ........................................................................................................................................................................................... 104
12.4 Inorganic Developments.................................................................................................................................................................................. 105
12.4.1 Overview ........................................................................................................................................................................................... 105
10
13. Company Profiles ...................................................................................................................................................... 107
13.1 Dasa Labs......................................................................................................................................................................................................... 107
13.1.1 Key Facts .......................................................................................................................................................................................... 107
13.1.2 Business Description ....................................................................................................................................................................... 107
13.1.3 Products and Services ..................................................................................................................................................................... 108
13.1.4 Financial Overview ........................................................................................................................................................................... 108
13.1.5 SWOT Analysis ................................................................................................................................................................................. 109
13.1.6 Key Developments........................................................................................................................................................................... 110
13.2 Quest Diagnostics Incorporated...................................................................................................................................................................... 111
13.2.1 Key Facts .......................................................................................................................................................................................... 111
13.2.5 SWOT Analysis ................................................................................................................................................................................. 115
13.3 SYNLAB - Solutions in Diagnostics .................................................................................................................................................................. 117
13.3.1 Key Facts .......................................................................................................................................................................................... 117
11
13.3.5 SWOT Analysis ................................................................................................................................................................................. 120
13.4 Grupo Fluery ..................................................................................................................................................................................................... 122
13.4.1 Key Facts .......................................................................................................................................................................................... 122
13.4.4 SWOT Analysis ................................................................................................................................................................................. 125
13.5 Hospital Israelita Albert Einstein ..................................................................................................................................................................... 127
13.5.1 Key Facts .......................................................................................................................................................................................... 127
13.5.5 SWOT Analysis ................................................................................................................................................................................. 129
13.6 Alliar .................................................................................................................................................................................................................. 131
13.6.1 Key Facts .......................................................................................................................................................................................... 131
12
13.6.5 SWOT Analysis ................................................................................................................................................................................. 134
13.7 Boris Berenstein Diagnostic Center ................................................................................................................................................................ 135
13.7.1 Key Facts .......................................................................................................................................................................................... 135
13.7.3 Products and Services..................................................................................................................................................................... 136
13.7.5 SWOT Analysis ................................................................................................................................................................................. 137
13.8 Clínica da Imagem do Tocantins ..................................................................................................................................................................... 138
13.8.1 Key Facts .......................................................................................................................................................................................... 138
13.8.5 SWOT Analysis ................................................................................................................................................................................. 139
13.9 Hermes Pardini ................................................................................................................................................................................................ 140
13
13.9.1 Key Facts .......................................................................................................................................................................................... 140
13.9.5 SWOT Analysis ................................................................................................................................................................................. 141
13.10 Abramed (BP Medicina Diagnostica) .............................................................................................................................................................. 143
13.10.1 Key Facts .......................................................................................................................................................................................... 143
13.10.3 Products and Services..................................................................................................................................................................... 144
13.10.5 SWOT Analysis ................................................................................................................................................................................. 145
14. Appendix .................................................................................................................................................................. 146

14.1 Glossary of Terms ............................................................................................................................................................................................ 146
14
LIST OF TABLES
Table 1. Brazil Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million) .......................................................................... 71
Table 2. Brazil Diagnostic Lab Market, by Testing Services– Revenue and Forecast to 2028 (USD Million)............................................................... 72
Table 3. Brazil Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million)....................................... 73
Table 4. Brazil Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million) ............................................................. 74
Table 5. Sao Paulo Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million) .................................................................. 76
Table 6. Sao Paulo Diagnostic Lab Market, by Testing Services– Revenue and Forecast to 2028 (USD Million) ....................................................... 77
Table 7. Sao Paulo Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million) ............................... 78
Table 8. Sao Paulo Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million) ...................................................... 79
Table 9. Rio de Janeiro Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million) ........................................................... 81
Table 10. Rio de Janeiro Diagnostic Lab Market, by Testing Services– Revenue and Forecast to 2028 (USD Million) ................................................ 82
Table 11. Rio de Janeiro Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million) ........................ 83
Table 12. Rio de Janeiro: Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million) .............................................. 84
Table 13. Salvador Diagnostic Lab Market, by Lab Type– Revenue and Forecast to 2028 (USD Million)...................................................................... 86
Table 14. Salvador Diagnostic Lab Market, by Testing Services – Revenue and Forecast to 2028 (USD Million) ........................................................ 87
Table 15. Salvador Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million) ................................. 88
Table 16. Salvador Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million) ........................................................ 89
Table 17. Brasilia: Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million) ...................................................................... 91
Table 18. Brasilia: Diagnostic Lab Market, by Testing Services – Revenue and Forecast to 2028 (USD Million) ......................................................... 92
15
Table 19. Brasilia: Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million) .................................. 93
Table 20. Brasilia: Diagnostic Lab Market, Revenue Source – Revenue and Forecast to 2028 (USD Million) .............................................................. 94
Table 21. Other Cities: Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million)............................................................... 96
Table 22. Other Cities: Diagnostic Lab Market, by Testing Services – Revenue and Forecast to 2028 (USD Million) .................................................. 97
Table 23. Other Cities: Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million) ........................... 98
Table 24. Other Cities: Diagnostic Lab Market, Revenue Source– Revenue and Forecast to 2028 (USD Million) ........................................................ 99
Table 25. Organic Developments Done by Companies.................................................................................................................................................... 104
Table 26. Inorganic Developments Done by Companies ................................................................................................................................................. 105
Table 27. Glossary of Terms, Blood Bank Market ............................................................................................................................................................ 146
16
LIST OF FIGURES
Figure 1. Diagnostic Labs Market Segmentation ............................................................................................................................................................... 22
Figure 2. Diagnostic Labs Market – By Geography ............................................................................................................................................................ 24
Figure 3. Brazil Diagnostic Labs Market Overview ............................................................................................................................................................. 25
Figure 4. Single/Independent Laboratories Held Largest Share of Diagnostic Labs Market .......................................................................................... 26
Figure 5. Brazil PEST Analysis.............................................................................................................................................................................................. 31
Figure 6. Impact Analysis of Drivers and Restraints Pertaining to Diagnostic Labs Market ........................................................................................... 36
Figure 7. Brazil Diagnostic Labs Market – Revenue Forecasts and Analysis – 2022- 2028 .......................................................................................... 37
Figure 8. Market Positioning of Key Players in Brazil Diagnostic Labs Market ................................................................................................................ 39
Figure 9. Brazil Diagnostic Labs Market – Comparative Company Analysis .................................................................................................................... 40
Figure 10. Brazil Diagnostic Labs Market – Growth Strategy Analysis ............................................................................................................................... 41
Figure 11. Market Share Analysis of Key Players in Brazil Diagnostic Labs Market .......................................................................................................... 45
Figure 12. Diagnostic Lab Market, by Lab Type 2022 & 2028 (%) ..................................................................................................................................... 46
Figure 13. Hospital-based Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ...................................................................... 47
Figure 14. Single/Independent Laboratories: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)................................................. 48
Figure 15. Physician Office Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)..................................................................... 49
Figure 16. Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ............................................................................................. 50
Figure 17. Diagnostic Lab Market Revenue Share, by Lab Type (2022 and 2028) .......................................................................................................... 51
Figure 18. Physiological Function Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ...................................................... 52
17
Figure 19. Endoscopy Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ......................................................................... 53
Figure 20. X-Ray Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .................................................................................. 54
Figure 21. CT Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ....................................................................................... 55
Figure 22. ECG Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) .................................................................................... 56
Figure 23. MRI Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ..................................................................................... 57
Figure 24. Echo Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ................................................................................... 58
Figure 26. General and Clinical Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ......................................................... 60
Figure 27. COVID-19 Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ........................................................................... 61
Figure 28. Esoteric Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million).............................................................................. 62
Figure 29. Specialized Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ........................................................................ 63
Figure 30. Non-Invasive Prenatal Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ...................................................... 64
Figure 32. Diagnostic Lab Market Revenue Share, by Revenue Source (2022 and 2028) .............................................................................................. 66
Figure 33. Healthcare Plan Operators and Insurers: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ...................................... 67
Figure 34. Out-of-Pocket Arrangements: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ......................................................... 68
Figure 35. Public System: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million) ................................................................................. 69
Figure 36. Brazil Diagnostic Lab Market Revenue and Forecast to 2028 (USD Million) ................................................................................................... 71
Figure 37. Brazil: Diagnostic Lab Market, by Cities, 2022 & 2028 (%) .............................................................................................................................. 74
18
Figure 38. Sao Paulo: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ....................................................................................... 75
Figure 39. Rio de Janeiro: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ................................................................................ 80
Figure 40. Salvador: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ......................................................................................... 85
Figure 41. Brasilia: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) ........................................................................................... 90
Figure 42. Other Cities: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million) .................................................................................... 95
Figure 43. Impact Of COVID-19 Pandemic in Brazil Market.............................................................................................................................................. 101
Figure 44. Growth Strategies Done by the Companies in the Market (%)........................................................................................................................ 103
19
1. Introduction
1.1 Scope of the Study
This research report provides insights into the Brazil diagnostic labs market. Lab tests and diagnostic procedures are used to check if a person's health
is normal. The increasing prevalence of various chronic and lifestyle-related diseases and a large old age population in the country are driving the
demand for the Brazil Diagnostic Labs Market.
The segmentation scope of the diagnostic labs market includes lab type, testing services, and revenue source. The market for diagnostic labs is analysed
based on Brazil. The report offers insights and in-depth analysis of the diagnostic labs market emphasizing on various parameters such as market trends,
technological advancements, market dynamics, and competitive landscape analysis of leading market players across Brazil.
1.2 The Insight Partners Research Report Guidance

• The report provides qualitative and quantitative trends of Brazil diagnostic labs market across lab type, testing services and revenue source.
The chapter also provides brief overview of the Brazil diagnostic labs market landscape.
• The report starts with the key takeaways (chapter two), highlighting the key trends and outlook of the Brazil diagnostic labs market.
• Chapter three provides a research methodology approach for the market.
• Chapter four further provides PEST analysis for the Brazil diagnostic labs market.
• Chapter five discusses the key industry dynamics in the diagnostic labs market, including factors that are driving the market, prevailing
deterrent, potential opportunities as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter six discusses the Brazil diagnostic labs market scenario, in terms of historical market revenues, and forecast till the year 2028.
20
• Chapter seven to ten discusses diagnostic labs market segments by lab type, testing services and revenue source across Brazil. They cover
market revenue forecast, and factors driving and governing growth.
• Chapter eleven describes impact analysis of Covid-19 across the Brazil diagnostic labs market.
• Chapter twelve describes the industry landscape analysis. It provides detailed description of various business activities such as market
initiatives, new developments, mergers and joint ventures in the Brazil diagnostic labs market.
• Chapter thirteen provides the detailed profiles of the key companies operating within the Brazil diagnostic labs market. The companies have
been profiled based on their key facts, business description, financial overview, product portfolio, SWOT analysis, and key developments.
• Chapter Fourteen i.e., the appendix is inclusive of a brief overview of the company, glossary of terms, contact information, and the disclaimer
section.
21
1.3 Market Segmentation
Figure 1. Diagnostic Labs Market Segmentation
Diagnostic Labs Market
Lab Type Testing Services Revenue Source
Hospital-Based Labs Physiological Function Testing Healthcare Plan Operators

and Insurers
Single/Independent
Laboratories General and Clinical Testing Out-of-Pocket
Physician Office Labs COVID-19 Testing Public System
Others Esoteric Testing
Specialized Testing
Non Invasive Prenatal Testing
Others
Source: The Insight Partners
22
The Brazil diagnostic labs market is segmented based on lab type, testing services, and revenue source. The segmentation in this research study has
been finalized post in-depth secondary research and extensive primary research. In addition, the market is also segmented on the basis of segments
offered by the leading participants in the industry in order to understand widely used market specific terminologies. Thus, we have incorporated the
segments of the research and have finalized the market segmentation.
1.3.1 Diagnostic Labs Market – By Lab Type

• Hospital-Based Labs
• Single/Independent Laboratories
• Physician Office Labs
• Others
1.3.2 Diagnostic Labs Market – By Testing Services

• Physiological Function Testing
• General and Clinical Testing
• COVID-19 Testing
• Esoteric Testing
• Specialized Testing
• Non Invasive Prenatal Testing
• Others
23
1.3.3 Diagnostic Labs Market – By Revenue Source
• Healthcare Plan Operators and Insurers
• Out-of-Pocket
• Public System
1.3.4 Diagnostic Labs Market – By Geography

• Rio de Janeiro
• São Paulo
• Salvador
• Brasilia
• Other Cities
Figure 2. Diagnostic Labs Market – By Geography
Brazil
São Paulo Rio de Janeiro Salvador Brasilia Other Cities
24
2. Diagnostic Labs Market – Key Takeaways
Figure 3. Brazil Diagnostic Labs Market Overview
Source: Expert Interviews, Surveys, Secondary Research, and the Insight Partners Analysis
25
Figure 4. Single/Independent Laboratories Held Largest Share of Diagnostic Labs Market
Source: Expert Interviews, Survey, Secondary Research, and The Insight Partners Analysis
Based on lab type, in 2022, the single/independent laboratories segment held the largest share of the market. However, hospital-based labs segment
is expected to grow at the fastest rate during the forecast period. This segment is likely to witness a lucrative growth because of Hospital-based
laboratories are responsible for conducting most of diagnostics tests, and generally perform more tests than all the other laboratory types, combined.
One of the major drivers for the competition between independent labs and hospital-based labs is the presence of various government regulations and
insurers.
26
3. Research Methodology
The Insight Partner’s research and analysis team consists of experienced professionals with advanced marketing and statistical expertise, market
research and consulting backgrounds in the healthcare industry.
27
The Insight Partners adheres to the codes of practice of the Market Research Society (www.mrs.org.uk) and Strategic and Competitive Intelligence
Professionals (www.scip.org).
28
The following methodology has been followed for the collection and analysis of data presented in this report:
3.1 Coverage
The objective of updating “The Insight Partners” coverage is to ensure it represents the most recent vision of the industry.
The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage. Companies that are
making news or are of particular interest due to their innovative approach, are prioritized.
3.2 Secondary Research

The research process begins with exhaustive secondary research using internal and external sources to obtain qualitative and quantitative information
related to each market. The secondary research sources that are typically referred to include but are not limited to:
• Company websites, annual reports, financial reports, broker reports and investor presentations
• Industry trade journals and other literature
• National government documents, statistical databases and market reports
• News articles, press releases and web-casts specific to the companies operating in the market
NOTE: All the financials considered in the Company Profile’s section have been standardized to US$. This has been achieved after converting the financials (for those not in US$) with respective currency
exchange rates of the particular year.
29
3.3 Primary Research
“The Insight Partners” conducts numerous primary interviews with industry participants and commentators to validate its data and analysis.
A typical research interview fulfils the following functions:
• Provides first-hand information on the market size, market trends, growth trends, competitive landscape and future outlook
• Validates and strengthens secondary research findings
• Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephonic interviews for each market, category, segment and sub-segment across the United States.
The participants who typically take part in such a process include, but are not limited to:
• Industry participants: VPs, business development managers, market intelligence managers and national sales managers
• Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the healthcare industry.
30
4. Diagnostic Labs Market – Market Landscape
4.1 Overview
The Brazil diagnostic labs market is estimated to grow at a CAGR of 10.5% from 2022 - 2028. Key factors driving the market such as rising prevalence
of ageing and chronic diseases are expected to drive the growth of the market. However, shortage of skilled healthcare professionals and high cost are
major factors hindering the market growth.
4.2 PEST Analysis

4.2.1 Brazil – PEST Analysis
Figure 5. Brazil PEST Analysis
• All pharmaceutical products, including IVD tests, must be

registered with Anvisa before being commercialized in
ECONOMIC
POLITICAL
• As per the National Health Expenditure Accounts, the Brazil
Brazil. It covers the registration of IVD products,
health care spending was 10..5% of total GDP in 2019,
establishing risk classification, registration of control
expected to reach 12.6% of total GDP. The increasing
procedures and labelling requirements and instructions for
healthcare spending are favoring the growth of the market.
IVD tests, including any associated instruments. Products
Brazil
are classified according to risks they pose to health.
• According to a 2021 report published by the Brazilian
TECHNOLOGICAL
Society of Diabetes (Sociedade Brasileira de Diabetes - • Diagnostics labs have started adopting new generation
SBD), the prevalence of diabetes in Brazil is 7.6% of the technological solutions to maximize a laboratory's
SOCIAL
population. Brazil ranks fifth highest in the number of productivity. For instance, Quest Diagnostics announced
diabetes cases, behind China, India, the United States and the availability of an at-home COVID-19 rapid antigen test
Pakistan. Diabetes is the third leading cause of mortality in service for consumer purchase available through
Brazil, with cardiovascular diseases and cancer being QuestDirect, a consumer-initiated testing platform
number one and two, respectively.
Source: The Insight Partners Analysis
31
5. Brazil Diagnostic Labs Market – Key Market
Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Ageing-Related Diseases and Chronic Diseases
According to World Population Ageing 2019, Brazil had 19.526 million people aged above 65 years in 2019, and the number is expected to reach
52.026 million by 2050. Older people are highly prone to chronic diseases. Therefore, increase in geriatric population raises the prevalence rate of liver
cancer and other diseases in the country. Additionally, leukemia is the most common cancer in children and has the incidence rates in developed
countries. As per the GLOBOCAN 2020, Brazil recorded 11,396 leukemia cases in males and females of all ages in 2020. Therefore, the demand for
acute myeloid leukemia treatment is rising in the country. Thus, owing to the increasing prevalence of aging-related diseases and chronic diseases,
healthcare innovation is essential to improve health services. For example, innovation in diagnostics with the support of information and communication
technology (ICT) is used in several settings that assist individuals in diagnosing, treating, and managing chronic diseases efficiently. Also, ICT
interventions in diagnostics provide solutions to some challenges associated with aging and chronic diseases. Thus, the aforementioned factors drive
the growth of the diagnostic lab market in Brazil.
5.1.2 Growing Use of Point-of-Care Diagnostic Products

Point-of-care diagnostics (POCD) play a vital role in the healthcare sector. Gradually, it has gained significant importance for rapid diagnosis of various
infectious and life-threatening diseases, such as cancer and diabetes, along with monitoring patients' health conditions. POC devices are efficient
diagnostic options to prevent delays in treatment, a crucial aspect in preventing high rates of mortality and transmission of infectious agents.
Furthermore, the COVID-19 pandemic has created a paradigm shift in the POC testing scenario in Brazil. It has driven research focused on developing
testing strategies that can be rapid and economical and can be implemented in the community as point-of-care testing. The COVID-19 pandemic has
32
accelerated the decentralization trend in testing. Reaching closer to patients outside of laboratories, hospitals, and homes enables a faster response to
clinical needs.
Scientists and entrepreneurs have made technological advancements to develop next-generation POC diagnostic devices based on the latest
technologies, such as artificial intelligence (AI) and Internet of Things (IoT), for different applications. Also, companies are developing affordable POC
diagnostic products with high specificity and sensitivity. For instance, in November 2020, Chembio Diagnostics, Inc., a leading point-of-care diagnostic
company focused on infectious diseases, announced that its subsidiary Chembio Diagnostics Brazil Ltda. received Agência Nacional de Vigilância
Sanitária (ANVISA) approval for the DPP SARS-CoV-2 Antigen test system in Brazil.
5.2 Market Restraints

5.2.1 Shortage of Skilled Healthcare Professionals and High Cost of Diagnostic Equipment
According to the WHO report, there is a drastic shortage of healthcare professionals or workers trained to use diagnostic equipment. For example,
ultrasound imaging (sonography) is widely used in Brazil. It shows movements of the body's internal organs and blood flowing through the blood vessels.
The procedure is safe with low risk for pregnant women. However, the risk may increase with unnecessary prolonged exposure to ultrasound energy or
in cases of untrained healthcare professionals operating the device. For example, the utility of diagnostic imaging devices by untrained professionals
could expose the foetus to prolonged and unsafe energy levels and could provide information that is interpreted incorrectly by the user.
Prices incurred by the hospitals and diagnostic centers for diagnostics procedures include facility and imaging equipment, technical team and support
staff, and the physician to plan and interpret the studies, prepare a permanently written report, and share the study results with referring
physician/provider. The high cost of diagnostic imaging equipment reduces its adoption. Such factors are responsible for sluggish growth of overall
diagnostic labs market during the forecast period.
5.3 Market Opportunities

5.3.1 Increasing Number of Strategic Collaborations and Partnerships
33
The players in the diagnostic labs market are involved in collaborations, acquisitions, joint ventures, and partnerships. Furthermore, the investment
levels in the market are rapidly growing. Various companies and investment firms are investing heavily in mergers, acquisitions, and collaborations.
Collaboration agreements between research institutions and companies, licensing agreements and partnerships among companies, and augmented
R&D investments in diagnostic labs are observed in the market growth.
5.3.2 For instance:

• In September 2021, Sweetch, a digital therapeutics innovator, announced partnership with Grupo Fleury, one of Brazil's leading healthcare
providers. As a part of substantial multi-year contract, Fleury will implement "Saúde iD telemedicine" services to improve healthcare outcomes
for patients suffering from chronic conditions.
• In April 2021, City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, announced the expansion
of its leading edge cancer expertise to South America through an education agreement with Hospital Israelita Albert Einstein, a top cancer
center in Latin America. The three-year agreement calls for City of Hope to share its specialized cancer expertise with Hospital Israelita Albert
Einstein’s oncology residents and clinical staff. Both institutes will explore potential innovative collaborations in precision oncology and
research.
• In August 2021, eMed, a telehealth company, announced collaboration with Quest Diagnostics, a world's leading provider of diagnostic
information services, for bringing clinician-guided rapid antigen testing for COVID-19 employers to decrease the risk of COVID-19 exposure at
workplaces. Through the collaboration, two companies will leverage the BinaxNOW COVID-19 Ag Card Home Test, a self-administered, nasal
swab antigen test offering results in 15 minutes.
• In August 2020, Dasa, the largest integrated healthcare network in Brazil, announced partnership expansion with SOPHiA GENETICS SA. The
partnership will offer the first decentralized Homologous Recombination Deficiency (HRD) analytics solution in Latin America. DASA
implemented SOPHiA DDMTM Radiomics and Trial Match solutions in 2020 to create the first multimodal approach in the region.
34
• In December 2020, HalioDx SAS, the immuno-oncology diagnostic company, announced the signing of distribution agreement with
Diagnosticos da America (DASA) for the commercialization of new product named "Immunoscore". Immunoscore is a unique diagnostic assay
for predicting the risk of recurrence and the response to chemotherapy regimen of patients suffering from early-stage colon cancer.
Such rising number of strategic partnerships and collaborations is expected to offer lucrative opportunities for the diagnostic labs market in Brazil during
the forecast period.
5.4 Future Trends

5.4.1 Use of Artificial Intelligence (AI) and Analytics in Diagnostic Equipment
Artificial intelligence helps improve numerous aspects of the healthcare industry, and diagnostic imaging technique is one of the fields that would benefit
greatly. Therefore, diagnostic imaging equipment manufacturers are incorporating AI in their products. For example, in September 2018, Nvidia
announced the launch of Nvidia Clara platform, a combination of software and hardware working together in diagnostic equipment. Such ground-
breaking technology can address the challenges of medical instruments and process enormous amounts of data generated every second that doctors
and scientists can easily interpret. Additionally, in August 2018, Google's DeepMind announced the launch of an AI system that can quickly detect over
50 eye disorders using routine medical scans. DeepMind's AI assistant for diagnostic imaging can automatically tackle eye-related issues by identifying
disease symptoms within seconds and prioritizing patients who seek urgent care.
AI supportive diagnostic equipment plays a vital role in diagnosing and classifying cancers. AI plays a pivotal role in the automated recognition of features
from sample medical images beyond the human's role while performing diagnostic imaging tasks. For example, automated AI applications enhanced
clinicians' qualitative potentials, including numerous tumor lesions at a time, prediction of the resultant tumor by referring to the various databases
within a short period, translation of phenotypic variations to genotypic, and persistent monitoring of patients. Further, AI generalizes disease imaging
techniques with minimal errors resulting in an earlier and significant diagnosis of diseases. Thus, the aforementioned factors will drive the future growth
of the diagnostic lab market in Brazil.
35
5.5 Impact Analysis
The figure below depicts the impact of driving and restraining factors on the diagnostic labs market. Driving factors such as the rising prevalence of
ageing-related diseases and chronic diseases and the growing use of point-of-care diagnostic products propel the market growth. However, the shortage
of skilled healthcare professionals and high cost of diagnostic equipment hamper the growth of the market.
Figure 6. Impact Analysis of Drivers and Restraints Pertaining to Diagnostic Labs Market
DRIVERS SHORT TERM MID TERM LONG TERM
Rising Prevalence of Ageing-Related Diseases and Chronic

Diseases
  
Rise in the Use of Point-of-care Diagnostic Products   
RESTRAINTS SHORT TERM MID TERM LONG TERM
Shortage of Skilled Healthcare Professionals and High Cost of
Diagnostic Equipment   
Short Term – 2 Years Mid Term – 5 Years Long Term – 10 Years
Low  Medium  High 
36
6. Diagnostic Labs Market – Brazil Analysis
6.1 Brazil Diagnostic Labs Market Revenue Forecasts and Analysis
The Brazil diagnostic labs market is expected to reach US$ 24,334.07 Mn in 2028 from US$ 13,367.60 in 2022. The market is estimated to grow with
a CAGR of 10.5% from 2022-2028. The key factors that are driving the growth of Brazil diagnostic labs market include rising prevalence of ageing and
chronic diseases and rise in the use of point-of-care diagnostic products. In addition, the growth opportunities such as increase in strategic collaboration
& partnerships in Brazil are likely to have a positive impact on the growth of the market in the coming years.
Figure 7. Brazil Diagnostic Labs Market – Revenue Forecasts and Analysis – 2022- 2028
11.0% 12.0%
25,000 10.6% 10.8%
10.2% 10.4%
9.7% 10.0%
8.3% 10.0%
20,000 8.1%
8.0%
15,000
24,334.07
21,922.59
6.0%
19,785.73
17,889.45
16,204.21
10,000
13,367.60
14,704.36
12,185.60
4.0%
11,271.68
5,000 2.0%
0 0.0%
2020 2021 2022 2023 2024 2025 2026 2027 2028
37
6.2 Brazil Diagnostic Labs Market, By Geography - Forecasts and Analysis
The growth in the region is driven by the key factors such as rising prevalence of ageing and chronic diseases and rise in the use of point-of-care
diagnostic products presence of major market players.
6.3 List of Distributors in Brazil-Diagnostic Labs Market

Country List of Distributors
• BIOSYS KOVALENT GROUP
• Geneability Produtos Médicos LTDA.
• Laboflex Scientific
• Biocontinental
• Sotelab Sociedade Tecnica de Laboratorio Ltda.
• Sellex S.A.C.
• Biogen
• Loccus Biotecnologia
• ARGOSLAB LTDA
• UNISCIENCE
• HORIBA Instruments Brasil
Brazil
• Lab Research do Brasil Ltda.
• Science Pro
• MEDIVAX
• DH Tech. Dev. Pte. Ltd. (SCIEX)
• DropSens
• Seegene Brazil (Seegene do Brasil Diagnosticos Ltda.)
• Spectrun
• Analiticaweb.com.br
• Pensabio Instrumentos de Tecnologia Ltda
• Sens Representações Comerciais, Ltda
• HalioDx SAS
38
• Allcrom
• Digigraf Distribuidora Comercio E Servicos SA.
• Kovalent Do Brazil Ltda
• PROFTAL DISTRIBUIDORA MEDICO HOSPITALAR LTDA
• MARKETPLACE SERVICOS INTERNACIONAIS LTDA
• Serion Brasil
• NL Comercio
• Nova Analitica Imp. Exp. Ltda
• Parque Científico y Tecnológico
• Medinova Life Sciences
Source: The Insight Partners Analysis, Website, Press Releases and Others
6.4 Company Analysis

6.4.1 Market Positioning of Key Players
Figure 8. Market Positioning of Key Players in Brazil Diagnostic Labs Market
DASA LABS
01 Headquarters - Bangalore, India
HOSPITAL ISRAELITA ALBERT

EINSTEIN
02
Headquarters – Sao Paulo, Brazil
39
6.4.2 Comparative Company Analysis
The comparative company analysis evaluates and categorizes in the Brazil diagnostic labs market based on product portfolio (product satisfaction,
product features, and availability), recent market developments: (merger & acquisition, new product launch & enhancement, investment & funding, and
award, agreement, collaboration, & partnership, recognition, & expansion) and geographic presence that aids businesses in better decision making and
understanding the competitive landscape. The report profoundly explores the recent significant developments by the leading vendors and innovation
profiles in the Brazil diagnostic labs market, including Dasa Labs, Quest Diagnostics Incorporated, SYNLAB-Solutions in Diagnostics, Grupo Fleury,
HOSPITAL ISRAELITA ALBERT EINSTEIN, Alliar, Boris Berenstein Diagnostic Center, Clinica da Imagem do Tocantins, Hermes Pardini, and
Abramed.Comparative company analysis provides an outlook analysis of the vendors' various business growth strategies and deliver valuable thoughts
at various stages while keeping up to date with the business and engaging players in the economic arena. All of the news gathered helps vendors in
understanding market potential and competitors' strengths and weaknesses.
Figure 9. Brazil Diagnostic Labs Market – Comparative Company Analysis
7.0
6.0
Dasa Labs
5.0 GRUPO FLEURY
Recent Developments
4.0
3.0
HOSPITAL ISRAELITA ALBERT
2.0 EINSTEIN
1.0
Hermes Pardini
0.0
2.5 3.0 3.5 4.0 4.5
-1.0 Product Portfolio
Analysis Impact : 0-1 Inadequate, 1.1-2 Satisfactory, 2.1-3 Good, 3.1-4 Outstanding
40
6.4.3 Growth Strategy Analysis
The below mentioned figure defines the various growth strategies opted by different companies in Brazil diagnostic labs market. The key company
initiating distinct growth strategy will have high potential to penetrate the in Brazil diagnostic labs market. The above data signifies the recent
development activities and how strong the companies in their respective field. Competitive growth strategies in terms of markets, help the vendor define
an alignment or fit between their capabilities and opportunities for future growth prospects. Analyze the landscape of It represents continuous merger
and acquisition strategy, geographical expansion, research and development, and optimal or advantageous suitability for adopting new product launch
strategies for further business expansion and growth during the forecast period. This graph enables to gauge the depth and breadth of the vendor’s and
one of the key understanding while developing the Brazil diagnostic labs market penetration strategies.
Figure 10. Brazil Diagnostic Labs Market – Growth Strategy Analysis
Growth Strategy Analysis
7
1 2
1 2
1 2 2
1 1 3
1 1 1 1
2 2 1 2
1 1 1
1 1
3 3 2 1 1
1
Dasa Labs GRUPO FLEURY Hermes Pardini HOSPITAL ISRAELITA Others
ALBERT EINSTEIN
Mergers Acquisitions Collaborations Agreements Partnerships Product Launches
41
Companies such as Dasa Labs, Quest Diagnostics Incorporated, SYNLAB-Solutions in Diagnostics, Grupo Fleury, HOSPITAL ISRAELITA ALBERT EINSTEIN,
Alliar, Boris Berenstein Diagnostic Center, Clinica da Imagem do Tocantins, Hermes Pardini, and Abramed are engaged in the strategic activities for
Brazil diagnostic labs market products.
• Partnership
HalioDx SAS, the immuno-oncology diagnostic company announced signing of a distribution agreement with DASA for new product commercialization
"Immunoscore" a unique diagnostic assay for predicting the risk of recurrence and the response to chemotherapy regimen of patients with early stage
colon cancer.
• Product Launch
Quest Diagnostics, the world's leader in diagnostic information services announced the availability of an at-home COVID-19 rapid antigen test service
for consumer purchase available through "QuestDirect" a consumer-initiated testing platform.
• Partnership
Sweetch, a digital therapeutics innovator announced partnership with Grupo Fleury one of Brazil's leading healthcare providers. The partnership aims
Fleury to implement " Saúde iD telemedicine" services to improve healthcare outcomes for patients living with chronic conditions as part of substantial
multi-year contract.
• Partnership
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes announced expansion of its leading-edge cancer
expertise to South America through an education agreement with Hospital Israelita Albert Einstein, a top cancer center in Latin America. The three-year
agreement calls for City of Hope to share its specialized cancer expertise with Hospital Israelita Albert Einstein’s oncology residents and clinical staff.
Both institutes will explore potential innovative collaborations in precision oncology and research.
42
• Collaboration
Siemens Healthineers announced collaboration with Hermes Pardini for transforming in-vitro diagnostic care delivery by developing "The Enterprise
Project" in Minas Gerias, Brazil. The Enterprise Project is largest and most complex clinical analysis laboratory known to date and is expected to be
capable of handling 110 million sample tubes annually upon completion. Additionally, the Enterprise Project delivers a 3D view of the laboratory
configuration, enabling operators to manage alerts, control instruments, and reagent monitoring remotely and observe test progression in real time.
6.4.4 Performance of Key Players

The Brazil diagnostic labs market majorly consists of the players such as Dasa Labs, Quest Diagnostics Incorporated, SYNLAB-Solutions in Diagnostics,
Grupo Fleury, HOSPITAL ISRAELITA ALBERT EINSTEIN, Alliar, Boris Berenstein Diagnostic Center, Clinica da Imagem do Tocantins, Hermes Pardini, and
Abramed.
6.4.4.1 Dasa Labs

Digital Assisted, Sensibly Augmented (DASA) company comprises technologists and healthcare specialists who are highly driving towards accuracy in
diagnosis, assisting patients suffering from life-threatening lung diseases. DASA Labs has partnerships with leading academic medical centers, large
global hospitals, and diagnostic centers, involving leading radiologists, pulmonologists, and data science experts. Additionally, DASA labs use Artificial
Intelligence (AI) that provides deep insights into any disease by application of deep learning algorithms for finding patterns in a carefully selected, large
number of high-resolution CT scans.
In August 2020, Dasa the largest integrated healthcare network in Brazil announced expanding of partnership with SOPHiA GENETICS SA. The
partnership will offer the first decentralized Homologous Recombination Deficiency (HRD) analytics solution in Latin America. Further, the partnership
further evolves SOPHiA DDMTM Radiomics and Trial Match solution in 2020 to create the first multimodal approach in the region.
In December 2020, HalioDx SAS, the immuno-oncology diagnostic company announced signing of a distribution agreement with DASA for new product
commercialization "Immunoscore" a unique diagnostic assay for predicting the risk of recurrence and the response to chemotherapy regimen of patients
with early stage colon cancer.
43
6.4.4.2 Grupo Fleury
Since its inception, Grupo Fleuro has been driving a passion for medicine, and the organization is one of the most respected medical and healthcare
organizations in Brazil. Groupo Fleuro has approximately 216 service units under the brands Fluery Medicina e Saúde, a+ Medicina Diagnóstica,
Laboratório Weinmann, Labs a+, Clínica Felippe Mattoso, Diagnoson a+, Weinmann Serdil, Instituto de Radiologia, Campana, Cedire, Centro de Patologia
Clínica, Diagmax, LAFE, Inlab, Papaz and SantéCorp. Through these brands Groupo Fleuro is present in markets of São Paulo, Rio de Janeiro, Rio Grande
do Sul, Paraná, Bahia, Pernambuco, Rio Grande do Norte, Distrito Federal and Maranhão. Additionally, Grupo Fleury partners with several renowned
hospitals for carrying out diagnoses, both clinical and imaging analysis with other specialties, offering diagnostic information of high added value for the
condition of work of doctors.
In September 2021, Sweetch, a digital therapeutics innovator announced partnership with Grupo Fleury one of Brazil's leading healthcare providers.
The partnership aims Fleury to implement " Saúde iD telemedicine" services to improve healthcare outcomes for patients living with chronic conditions
as part of substantial multi-year contract.
44
6.5 Market Share Analysis of Brazil Diagnostic Labs Market
Figure 11. Market Share Analysis of Key Players in Brazil Diagnostic Labs Market
15.85%
5.89%
3.02%
2.78%
0.23%
72.22%
DASA LABS GRUPO FLEURY

Hermes Pardini HOSPITAL ISRAELITA ALBERT EINSTEIN
ALLIAR MéDICOS Others
The Brazil diagnostic labs market majorly consists of the players Dasa Labs, Quest Diagnostics Incorporated, SYNLAB-Solutions in Diagnostics, GRUPO
FLEURY, HOSPITAL ISRAELITA ALBERT EINSTEIN, Alliar, Boris Berenstein Diagnostic Center, Clinica da Imagem do Tocantins, Hermes Pardini, and
Abramed.
45
7. Brazil Diagnostic Lab Market Revenue and Forecasts
To 2028 – Lab Type
7.1 Overview
Diagnostic Lab market based on the lab type is segmented into single/independent laboratories, hospital-based labs, physician office labs, and others.
In 2022, the hospital-based laboratories segment is likely to hold the largest share of the market. However, the single/independent laboratories segment
is expected to grow at the fastest CAGR of 10.8% during the coming years.
7.2 Diagnostic Lab Market, by Lab Type 2022 & 2028 (%)
Figure 12. Diagnostic Lab Market, by Lab Type 2022 & 2028 (%)
4.85% 4.07%
4.15% 4.89%
Hospital-Based
Laboratories
Single/Independent
Laboratories
49.40% 48.77%
2022 2028
41.60% Physician Office Labs 42.26%
Others
46
The hospital-based laboratories segment is likely to lead the market in 2022 with a share of 49.40% and is expected to retain its dominance during the
forecast period, thereby accounting for 48.77% of the total market by 2028.
7.3 Hospital-based Labs

7.3.1 Overview
Hospital-based laboratories generally perform more tests than all the other laboratory types, combined. One of the major drivers for the competition
between independent labs and hospital-based labs is the presence of various government regulations and insurers. For instance, the CMS (Federal
Centers for Medicare and Medicaid Services) provides more funds for hospital-based laboratory services as compared to independent laboratories. In
addition, medical personnels and clinicians are available 24/7 in hospital-based labs to deliver advanced and experienced diagnostic solutions. Owing
to the presence of electronic health records, hospital-based labs have the distinct advantage of faster delivery of test results to doctors and patients.
7.3.2 Hospital-based Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for hospital-based labs segment is likely to be valued at US$ 6,603.12 million in 2022 and is projected to reach US$ 11,867.23 million by
2028; it is expected to grow at a CAGR of 10.3% during the forecast period.
Figure 13. Hospital-based Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
11,867.23
10,713.92
9,690.20
8,780.18
7,970.07
6,603.12
7,247.87
6,032.20
5,591.82
2020 2021 2022 2023 2024 2025 2026 2027 2028
Source: The Insight Partners Analysis, Primary Interview, and Secondary Source
47
7.4 Single/Independent Laboratories
7.4.1 Overview
In the last few years, single laboratories or independent laboratories are preferred more than hospital laboratories as they are cost effective and provide
results faster than hospital laboratories. The costs of performing laboratory tests in one core facility are often lower than the performing the same tests
in individual hospital laboratories, mainly because of the increased test volume. Furthermore, the duplication of laboratory services can be reduced, by
forming a strategic alliance with hospital-based laboratories in the country. Moreover, external laboratory consolidation, in which allied hospital
laboratories share services or cooperate with each other at least at some level is beneficial for lowering costs/test and entering the outreach diagnostic
testing. The increased demand for at-home testing to diagnose and monitor disease is likely to spur the growth of the Diagnostic Lab market for the
single/independent laboratories segment.
7.4.2 Single/Independent Laboratories: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for Single/Independent Laboratories segment is likely to be valued at US$ 5,560.81 million in 2022 and is projected to reach US$ 10,284.23
million by 2028; it is expected to grow at a CAGR of 10.8% during the forecast period.
Figure 14. Single/Independent Laboratories: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
10,284.23
9,240.03
8,317.72
7,500.92
6,776.51
6,133.10
5,560.81
5,055.66
4,664.01
2020 2021 2022 2023 2024 2025 2026 2027 2028
48
7.5 Physician Office Labs (POL)
7.5.1 Overview
The constantly increasing number of physicians and physician groups is preferring to undertake a part or entire volume of diagnostics lab in-house to
improve patient care and boost operative incomes. In-house lab practices are called physician office laboratory (POL). In-house testing facilitates
physicians to become self-reliant and provides diagnosis results faster than outsourced lab tests. POLs reduce the chances of loss or deterioration of
test samples, enhancing the confidence regarding the accuracy of results. The emergence and easy availability of easy-to-use microelectronic and
microfluidic instruments offer excellent accuracy and control, which makes physician office labs feasible for smaller physician offices and enable some
physicians to perform tests for other doctors.
7.5.2 Physician Office Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for physician office labs segment is likely to be valued at US$ 648.66 million in 2022 and is projected to reach US$ 1,191.07 million by
2028; it is expected to grow at a CAGR of 10.7% during the forecast period.
Figure 15. Physician Office Labs: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
1,191.07
1,071.51
965.68
871.87
788.59
714.56
648.66
590.44
545.35
2020 2021 2022 2023 2024 2025 2026 2027 2028
49
7.6 Others
7.6.1 Overview
A few other diagnostics lab types are ambulatory surgical centers, research labs, and research institutes. The growing need to reduce escalating
healthcare costs; shift from inpatient to outpatient surgical procedures; and growing demand for IT solutions, such as mhealth, telehealth, and remote
patient monitoring, for better patient management fuel the diagnostics lab market growth for the ambulatory surgical centers segment. Also, the
increasing focus on drugs development for various chronic diseases and ongoing research on early diagnosis methods drive the market growth for the
research institutes segment.
7.6.2 Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for others segment is likely to be valued at US$ 555.01 million in 2022 and is projected to reach US$ 991.53 million by 2028; it is expected
to grow at a CAGR of 10.2% during the forecast period.
Figure 16. Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
991.53
897.13
812.14
736.48
669.03
608.83
555.01
507.30
470.50
2020 2021 2022 2023 2024 2025 2026 2027 2028
50
to 2028– by Testing Services
8.1 Overview
The diagnostic labs market, by type is segmented into physiological function testing, general and clinical testing, esoteric testing, specialized testing,
non-invasive prenatal testing, COVID-19 testing, and others. The physiological function testing segment held the largest share of the market in 2022.
However, the esoteric testing segment is anticipated to register the highest CAGR of 14.1% in the market during the forecast period.
8.2 Diagnostic Lab Market Revenue Share, by Lab Type (2022 and 2028)
Figure 17. Diagnostic Lab Market Revenue Share, by Lab Type (2022 and 2028)
51
The physiological function testing segment is expected to lead the market in 2022 with a share of 36.22% and is expected to retain its dominance during
the forecast period, thereby accounting for 30.55% of the total market by 2028.
8.3 Physiological Function Testing

8.3.1 Overview
Physiological function testing falls under medical practices where doctors examine and consult patients in medical institutions. Physiological function
testing consists of ECG exam, echo exam, X-ray, endoscopy, CT-scan, MRI, Plethysmography, urea breath test, respiratory function testing,
electroencephalography, neurophysiological tests, and ultrasound. The growing prevalence of infectious and chronic diseases and need of early
detection of these diseases drive the growth of the diagnostic lab market for this segment.
8.3.2 Physiological Function Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for accessories segment is likely to be valued at US$ 3,964.71 million in 2022 and is projected to reach US$ 7,432.70 million by 2028. The
growth rate of this segment is projected to be 11.0% during the forecast period.
Figure 18. Physiological Function Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
7,432.70
6,663.80
5,985.07
5,385.06
4,853.86
3,964.71
4,382.89
3,596.15
3,309.79
2020 2021 2022 2023 2024 2025 2026 2027 2028
52
8.3.3 Endoscopy Market
8.3.3.1 Overview
Endoscopy is a minimally invasive procedure that is done for diagnosis, prevention, and treating complications associated with the visceral organs.
Endoscopy devices are equipped with several other parts, including light source and camera, at the tip of the endoscopes. These instruments at the tip
of endoscopes help the medical professionals analyze the internal organ of interest. Technological advancements in endoscopes for early detection of
diseases and rise in prevalence rate of diseases that require endoscopy fuel the diagnostic lab market growth for the segment. In addition, favorable
FDA approvals and reimbursement policies pertaining to endoscopy devices, surge in patient preference for minimally invasive surgeries, and shorter
recovery time and minimal postoperative complications bolster the market growth for the endoscopy segment.
8.3.3.2 Endoscopy Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for endoscopy market segment is likely to be valued at US$ 1,305.04 million in 2022 and is projected to reach US$ 2,398.08 million by
2028. The growth rate of this segment is projected to be 10.7% during the forecast period.
Figure 19. Endoscopy Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
2,398.08
2,157.26
1,944.05
1,755.01
1,587.17
1,437.93
1,305.04
1,187.63
1,096.65
2020 2021 2022 2023 2024 2025 2026 2027 2028
53
8.3.4 X-Ray Market
8.3.4.1 Overview
X-rays are a form of electromagnetic radiation and have wide application in medical imaging tools. They are used to view, monitor, and diagnose bone
fractures, cancer, abdominal pain, joint injuries, and infection. X-ray equipment is widely used in the detection of breast cancer, dental issues, chest
imaging, and orthopedic disorder. The recent technological developments in X-ray equipment and the growing prevalence of cancer are major factors
expected to drive the diagnostic lab market growth for the X-ray segment. According to data published by the World Cancer Research Fund International
in 2018, lung cancer is the most common type of cancer worldwide, which accounted for around 12.3% of the total number of new cases diagnosed in
2018. The number of cancer patients across the globe is expected to rise to 19 million by 2024. Therefore, the rising prevalence of cancer is driving the
market growth for the X-ray segment.
8.3.4.2 X-Ray Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for x-ray market segment is likely to be valued at US$ 850.04 million in 2022 and is projected to reach US$ 1,615.58 million by 2028. The
Figure 20. X-Ray Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
1,615.58
1,445.17
1,295.03
1,162.55
1,045.48
941.87
850.04
769.24
706.34
2020 2021 2022 2023 2024 2025 2026 2027 2028
54
8.3.5 CT Market
8.3.5.1 Overview
A steep rise in the application of CT scan for detecting various diseases and disorders increases the number of CT scan tests carried in the countries. In
past a few years, the field of computed tomography has witnessed significant technological advancements, including low-dose emergence and
automated CT scanners. Technological advancements, such as the integration of artificial intelligence (AI) and the development of accessories to
enhance image quality obtained by conventional CT scanners, are fuelling the diagnostic lab market growth for the segment. In May 2021, Siemens
Healthineers launched a new CT scanner, Somatom X. It is a high-speed, high-resolution CT scanner with an intelligent operation approach that makes
procedures easier for medical staff and patient. In September 2021, GE Healthcare introduced a new CT system, Revolution Ascend, which uses AI to
improve operational efficiency and patient comfort.
8.3.5.2 CT Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for CT market is likely to be valued at US$ 609.27 million in 2022 and is projected to reach US$ 1,156.24 million by 2028. The growth rate
of this segment is projected to be 11.3% during the forecast period.
Figure 21. CT Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
1,156.24
1,034.52
927.26
832.60
748.95
674.90
609.27
506.56
551.51
2020 2021 2022 2023 2024 2025 2026 2027 2028
55
8.3.6 ECG Market
8.3.6.1 Overview
An electrocardiogram (ECG) records the electrical signals in heart. It is a common and painless test used to quickly detect heart problems and monitor
the heart's health. Sensors attached to the skin detect the electrical signals produced by heart each time it beats. The growing prevalence of cardiac
arrhythmia and increasing demand for ambulatory monitoring devices bolster the diagnostic lab market growth for the ECG segment. In addition, the
increase in geriatric population, technological advancements in diagnostic testing, and advancements in ECG equipment and management systems are
expected to boost the market growth for the segment during the forecast period. The shift from paper ECG review to electronic ECG equipment and
management systems over the past decade has helped to improve efficiency. Moreover, improvements in the ECG equipment and management system,
such as the development of open platform, have improved integration with Cardiovascular Information Systems (CVIS), smartphones, and cloud-based
systems.
8.3.6.2 ECG Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for ECG market segment is likely to be valued at US$ 461.12 million in 2022 and is projected to reach US$ 871.14 million by 2028. The
Figure 22. ECG Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
871.14
780.03
699.69
628.74
565.99
510.42
461.12
383.94
417.71
2020 2021 2022 2023 2024 2025 2026 2027 2028
56
8.3.7 MRI Market
8.3.7.1 Overview
In August 2020, the US Food and Drug Administration (FDA) cleared two Siemens Healthineers AI-based software assistants in the AI-Rad Companion
family. Both new software help free radiologists from routine activities during MRI exams. The AI-Rad Companion Brain MR for morphometry analysis
automatically segments the brain in MRI images, measures brain volume, and marks volume deviations. The AI-Rad Companion Prostate MR for biopsy
support automatically segments the prostate on MRI images and enables radiologists to mark lesions, facilitating targeted prostate biopsies. Moreover,
the development of cardiac pacemaker-compatible MRI systems and technological advancements in MRI technologies are expected to propel the
diagnostic lab market growth for the segment during the forecast period. MRI can provide early detection of neurological, orthopedic, and cardiovascular
condition that helps increase the success rates of the treatment. Therefore, the adoption of MRI is increasing across Brazil, which accelerates the overall
market growth for the segment.
8.3.7.2 MRI Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for MRI market segment is likely to be valued at US$ 413.22 million in 2022 and is projected to reach US$ 792.35 million by 2028. The
Figure 23. MRI Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
792.35
707.74
633.28
567.66
509.74
458.54
413.22
342.34
373.38
2020 2021 2022 2023 2024 2025 2026 2027 2028
57
8.3.8 Echo Market
8.3.8.1 Overview
Echocardiography, also known as cardiac echo test is an ultrasound of the heart to help the doctor monitor the heart and valve functioning. The sound
waves in echocardiography generates moving pictures of heart, which helps in studying the size and shape of heart. Over the past few years, cardiac
ultrasound or echocardiography vendors have introduced several new products accelerate the flow of cardiac imaging. Artificial Intelligence (AI) is
becoming one of the fastest growing phenomenon in the field of echocardiography, which is helping to automate the functions of devices and systems.
Companies developing echocardiography instruments are teaming up with software companies to develop AI apps that are capable of calculating ejection
fraction in seconds. These software are accelerating diagnosis using echocardiography as they support as they physicians through cardiac scanning with
auto labeling, guiding, and grading.
8.3.8.2 Echo Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for echo market is likely to be valued at US$ 144.71 million in 2022 and is projected to reach US$ 283.53 million by 2028. The growth rate
of this segment is projected to be 11.9% during the forecast period.
Figure 24. Echo Market: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
283.53
252.38
225.04
201.00
179.84
161.18
144.71
118.97
130.26
2020 2021 2022 2023 2024 2025 2026 2027 2028
58
8.3.9 Others
8.3.9.1 Overview
Other segment consists of Plethysmography, urea breath test, respiratory function testing, electroencephalography, neurophysiological tests, and
ultrasound. There are more than 600 neurological disorders, including brain tumor, epilepsy, Parkinson’s disease, Alzheimer’s etc. These disorders were
ranked as the leading cause group of Disability Adjusted Life Years (DALYs), which is the number of years lost due to ill-health, disability or early death.
According to the Alzheimer's Association Brazil, in Brazil, more than 1 million people are suffering from some form of dementia. The increasing number
of neurological disease cases is propelling the demand for devices used in the treatment of such disorders.
8.3.9.2 Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for others segment is likely to be valued at US$ 181.31 million in 2022 and is projected to reach US$ 315.78 million by 2028. The growth
rate of this segment is projected to be 9.7% during the forecast period.
59
8.4 General and Clinical Testing
8.4.1 Overview
Rising awareness about the early diagnosis of diseases using general and clinical testing is the main reason fueling the Brazil diagnostic lab market
growth for the general and clinical testing segment. The rising demand for clinical laboratory test is driven by the growing investments in the diagnosis
of target diseases, including cardiovascular diseases, diabetes, and tuberculosis. General and clinical testing is used to diagnose diabetes through
measuring the blood sugar levels in the body. According to an article published by the International Diabetes Federation in 2019, around 463 million
adults were suffering from diabetes, and the count is estimated to reach 700 million globally by 2045. The rise in prevalence of diabetes is bolstering
the market growth for the segment. Also, the growing prevalence of infectious diseases detected by general and clinical testing, such as HIV, Hepatitis
B, and flu, fuels the market growth for the segment.
8.4.2 General and Clinical Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for the general and clinical testing segment is likely to be valued at US$ 2,691.44 million in 2022 and is projected to reach US$ 5,135.34
million by 2028. The growth rate of this segment is projected to be 11.4% during the forecast period.
Figure 26. General and Clinical Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
5,135.34
4,591.07
4,111.63
3,688.67
3,314.99
2,984.38
2,691.44
2,433.72
2,232.92
2020 2021 2022 2023 2024 2025 2026 2027 2028
60
8.5 COVID-19 Testing
8.5.1 Overview
With the declaration of the COVID-19 pandemic in March 2020, diagnostic testing became a crucial part of the disease management. With the
unavailability of the vaccine at that time and many uncertainties regarding the cure, reliable tests were essential to help contain the spread of the
disease. Initially, RT-PCR was the only available test to detect the presence of SARS‑CoV‑2, a viral agent that causes COVID-19. Later serological method
or immunological testing was used to detect the virus. Immunologic testing can be done via two different techniques— enzyme-linked immunosorbent
assay (ELISA) and immunochromatographic assays. The sudden rise in the number of COVID-19 cases increased the R&D demand in the diagnostics
process, government funding, and diagnostics activities, which fueled the Brazil diagnostic lab market growth for the segment. Owing to the increasing
number of COVID-19 cases between 2020 and 2021, increased focus of government to prevent the spread of the virus, lack of therapeutic treatments
and vaccines, and a rise in demand for timely diagnostics were observed, which bolstered the market growth for the COVID-19 testing segment.
8.5.2 COVID-19 Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for COVID-19 testing segment is likely to be valued at US$ 2,726.24 million in 2022 and is projected to reach US$ 4,180.67 million by
2028. The growth rate of this segment is projected to be 7.4% during the forecast period.
Figure 27. COVID-19 Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
4,180.67
3,884.47
3,612.19
2,726.24
3,361.94
2,549.94
3,131.94
2,920.55
2,217.31
2020 2021 2022 2023 2024 2025 2026 2027 2028
61
8.6 Esoteric Testing
8.6.1 Overview
The Brazil diagnostic lab market growth for the esoteric testing segment is mainly driven by an increase in prevalence of infectious, chronic, and rare
genetic diseases, rise in demand for real time polymerase chain reaction (RT-PCR) and enzyme linked immunosorbent assay (ELISA), and advancement
in technology for esoteric testing. The prevalence of infectious diseases, including Dengue, Hepatitis B, C, HIV, Malaria, and Tuberculosis, is increasing
at an alarming rate. The awareness of the esoteric tests is growing for the early and effective diagnosis of such diseases. The technological
advancements in esoteric tests are offering expedited results with high efficacy, detection limits, and sensitivity. The rising use of esoteric testing such
as DNA sequencing, NGS technologies, and whole genome sequencing in the early diagnosis of cancer, precision, and personal medicine are also
bolstering the market growth for the segment.
8.6.2 Esoteric Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for esoteric testing segment is likely to be valued at US$ 1,144.61 million in 2022 and is projected to reach US$ 2,530.58 million by 2028.
The growth rate of this segment is projected to be 14.1% during the forecast period.
Figure 28. Esoteric Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
2,530.58
2,212.55
1,936.23
1,695.88
1,486.54
1,303.99
1,006.21
1,144.61
896.37
2020 2021 2022 2023 2024 2025 2026 2027 2028
62
8.7 Specialized Testing
8.7.1 Overview
Specialized testing is a type of testing that is specifically decided according to the need of the population. The testing offers stimulation and tolerance
testing, bone marrow collections, and sweat chloride testing for Cystic Fibrosis. Cystic fibrosis is an inherited disease characterized by the build-up of
thick, sticky mucus that can damage many organs of the body. The prevalence of cystic fibrosis disease among Americans drive the diagnostic lab
market growth for the specialized testing segment.
8.7.2 Specialized Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for specialized testing segment is likely to be valued at US$ 642.37 million in 2022 and is projected to reach US$ 1,269.04 million by 2028.
Figure 29. Specialized Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
1,269.04
1,128.31
1,004.82
896.30
800.81
716.65
577.26
642.37
526.27
2020 2021 2022 2023 2024 2025 2026 2027 2028
63
8.8 Noninvasive Prenatal Testing
8.8.1 Overview
The diagnostic lab market growth for the noninvasive prenatal testing segment is driven by the high risk of chromosomal abnormalities with increasing
maternal age, growing preference for noninvasive techniques over invasive methods, improving reimbursement scenario for noninvasive prenatal
testing, and increasing awareness related to noninvasive prenatal testing.
The proportion of women conceiving at or above the age of 35 in prenatal medical and obstetrical services has increased significantly over the past 30
years. This demographic change has had important implications to women planning a pregnancy and may also lead to several chromosomal
abnormalities. For instance, the chance of having a child with Down syndrome increases over time. The risk is about 1 in 1,250 for a woman who
conceives at the age 25. It increases to about 1 in 100 for a woman who conceives at age 40. As the percentage of pregnancies in women of advanced
age (~35 years or above) has increased, there is an increasing demand for prenatal genetic counseling that helps predict the risk of fetal chromosomal
abnormalities depending on age, thereby fueling the Brazil diagnostic lab market growth for the noninvasive prenatal testing segment.
8.8.2 Non-Invasive Prenatal Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for non-invasive prenatal testing segment is likely to be valued at US$ 315.09 million in 2022 and is projected to reach US$ 662.71 million
by 2028. The growth rate of this segment is projected to be 13.2% during the forecast period.
Figure 30. Non-Invasive Prenatal Testing: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
662.71
583.60
514.60
454.35
401.67
355.53
279.83
315.09
252.01
2020 2021 2022 2023 2024 2025 2026 2027 2028
64
8.9 Others
8.9.1 Overview
The others segment consists of genetic testing, point-of-care testing, antigen testing, thyroid test, and cross match test. The availability of efficient and
highly sensitive methods of DNA sequencing for genetic testing offers new approaches for initial screening test. Moreover, the development of NGS, a
rapidly evolving technology that enables sequencing of a whole genome or a part of genome, and the rapid extraction of genetic information from
biological materials will fuel the adoption of genetic tests in the future. Genetic testing helps estimate the chances of developing cancer throughout an
individual’s lifetime by examining specific changes in proteins, chromosomes, and genes; resulting in reduced morbidity, less expensive treatment, and
greater survival probability. This fuels the diagnostic lab market growth for the others segment.
8.9.2 Others: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for others segment is likely to be valued at US$ 1,883.14 million in 2022 and is projected to reach US$ 3,123.02 million by 2028. The
3,123.02
2,858.79
2,621.18
2,407.25
1,883.14
2,214.41
2,040.38
1,837.01
1,742.51
2020 2021 2022 2023 2024 2025 2026 2027 2028
65
to 2028 – Revenue Source
9.1 Overview
The diagnostic labs market by revenue source, is segmented into healthcare plan operators and insurers, out-of-pocket, and public system. The
healthcare plan operators and insurers segment are likely to hold the largest share of the market in 2022, and the healthcare plan operators and
insurers segment is anticipated to register the highest CAGR of 10.7% of the market during the forecast period.
9.2 Diagnostic Lab Market Revenue Share, by Revenue Source (2022 and 2028)
Figure 32. Diagnostic Lab Market Revenue Share, by Revenue Source (2022 and 2028)
19.95% Healthcare Plan 20.04%

Operators and
Insurers
Out-of-Pocket
2022 49.84% 2028 50.43%
30.21% Public System 29.53%
The healthcare plan operators and insurers segment are likely to lead the market in 2022 with a share of 49.84% and is expected to retain its dominance
during the forecast period, thereby accounting for 50.43% of the total market by 2028.
66
9.3 Healthcare Plan Operators and Insurers
9.3.1 Overview
There has been an increase in the number of private insurers that offer customizable insurance products. Many of the provisions provided by Brazil
Government are similar to the Affordable Care Act that is they focus on the expansion of healthcare insurance coverage. It generates incentives for
employers to provide health coverage and compels people who are not covered under the insurance program of their governments or employers to
purchase private healthcare insurance.
In Brazil, private health insurance is voluntary and supplementary to SUS, and it is regulated by the National Agency of Supplementary Health. In 2018,
~23% of Brazilians had private medical/hospital insurance, and ~9.6% had dental insurance. Moreover, ~70% of beneficiaries, who receive health
insurance facility, receive their private health insurance as an employment benefit. Private health plan operators offer healthcare services through their
facilities or through accredited healthcare organizations. Alternatively, they can reimburse enrollees for purchased health care services.
9.3.2 Healthcare Plan Operators and Insurers: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for healthcare plan operators and insurers segment is likely to be valued at US$ 6,662.04 million in 2022 and is projected to reach US$
12,271.30 million by 2028. The growth rate of this segment is projected to be 10.7% during the forecast period.
Figure 33. Healthcare Plan Operators and Insurers: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
12,271.30
11,033.68
9,938.73
8,968.58
8,107.73
6,662.04
7,342.78
6,060.91
5,595.18
2020 2021 2022 2023 2024 2025 2026 2027 2028
67
9.4 Out-of-Pocket Arrangements
9.4.1 Overview
The out-of-pocket expenditures (OOPEs) may be catastrophic or impoverishing. In Brazil, out-of-pocket expenditures account for ~27% of total health
expenditures. Excessive reliance on out-of-pocket arrangements creates a disproportionate burden on low-income individuals, accentuating income
inequality and the medical poverty trap. According to an article by Commonwealth Fund, in 2019, more than 5.3% of households experienced such high
health expenditures that they had to forgo paying for non-health-related items.
9.4.2 Out-of-Pocket Arrangements: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for out-of-pocket organizations segment is likely to be valued at US$ 4,038.87 million in 2022 and is projected to reach US$ 7,185.43
million by 2028. The growth rate of this segment is projected to be 10.1% during the forecast period.
Figure 34. Out-of-Pocket Arrangements: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
7,185.43
6,498.34
5,887.50
5,343.66
4,858.80
4,038.87
4,425.91
3,695.72
3,431.49
2020 2021 2022 2023 2024 2025 2026 2027 2028
68
9.5 Public System
9.5.1 Overview
The Brazilian public healthcare system is known as the United Health System or Sistema Único de Saúde (SUS), which is free and universal to all.
Healthcare is a constitutional right in the country. The SUS health insurance program covers a large number of people across a greater continuous
landmass, and operates more clinics and hospitals than any other healthcare program in the world. People traveling to Brazil are also covered for
emergency services. Brazil has bilateral agreements with Portugal, Spain, Greece, Italy, Uruguay, Argentina, Chile, and Cape Verde, which guarantee
access to medical services for foreigners who pay into the INSS social security system. All foreign citizens with legal residency status—including those
with permanent residency, those on work visas, and international students—can apply for SUS insurance.
9.5.2 Public System: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
The market for public system segment is likely to be valued at US$ 2,666.69 million in 2022 and is projected to reach US$ 4,877.34 million by 2028.
Figure 35. Public System: Diagnostic Lab Market – Revenue and Forecast to 2028 (US$ Million)
4,877.34
4,390.56
3,959.50
3,577.21
3,237.67
2,935.68
2,666.69
2,428.97
2,245.01
2020 2021 2022 2023 2024 2025 2026 2027 2028
69
to 2028 – Region Analysis
10.1 Brazil: Diagnostic Lab Market
10.1.1 Overview
The diagnostic labs market in Brazil is further segmented into the Rio de Janeiro, Sao Paulo, Salvador, Brasilia, and others. The US held the largest share
of the Brazil diagnostic labs market in 2022. Increasing demand for diagnostic test for various diseases, technological advancements, and use of AI for
proper imaging of diagnosis are projected to accelerate the growth of the diagnostic labs market.
10.1.2 Brazil: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
The Brazil diagnostic labs Market was valued at US$ 13,367.60 million in 2022 and is projected to reach US$ 24,334.07 million by 2028; it is expected
70
Figure 36. Brazil Diagnostic Lab Market Revenue and Forecast to 2028 (USD Million)
11.0% 12.0%
25,000 10.6% 10.8%
10.2% 10.4%
9.7% 10.0%
8.3% 10.0%
20,000 8.1%
8.0%
15,000
24,334.07
21,922.59
6.0%
19,785.73
17,889.45
16,204.21
10,000
13,367.60
14,704.36
12,185.60
4.0%
11,271.68
5,000 2.0%
0 0.0%
2020 2021 2022 2023 2024 2025 2026 2027 2028
10.1.3 Brazil: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million)
Table 1. Brazil Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Lab Type 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Hospital-Based Labs 5,172.40 5,591.82 6,032.20 6,603.12 7,247.87 7,970.07 8,780.18 9,690.20 10,713.92 11,867.23 10.3%
Single/Independent
4,293.36 4,664.01 5,055.66 5,560.81 6,133.10 6,776.51 7,500.92 8,317.72 9,240.03 10,284.23 10.8%
Laboratories
Physician Office Labs 502.62 545.35 590.44 648.66 714.56 788.59 871.87 965.68 1,071.51 1,191.07 10.7%
Others 435.39 470.50 507.30 555.01 608.83 669.03 736.48 812.14 897.13 991.53 10.2%
Source: The Insight Partners Analysis, Primary Interviews, Magazines and Journals, and Secondary Sources
71
The diagnostic labs market for the hospital-based labs segment was worth US$ 6,032.20 million in 2021 and is projected to reach US$ 11,867.23
million by 2028; it is expected to grow at a CAGR of 10.3% during the forecast period. The market for the single/independent laboratories segment is
estimated to be worth US$ 10,284.23 million by 2028 and is expected to grow at a CAGR of 10.8% during the forecast period.
10.1.4 Brazil: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million)
Table 2. Brazil Diagnostic Lab Market, by Testing Services– Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Testing Services 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Physiological Function
3,771.69 3,309.79 3,596.15 3,964.71 4,382.89 4,853.86 5,385.06 5,985.07 6,663.80 7,432.70 11.0%
Testing
General and Clinical
2,585.67 2,232.92 2,433.72 2,691.44 2,984.38 3,314.99 3,688.67 4,111.63 4,591.07 5,135.34 11.4%
Testing
COVID-19 Testing 94.79 2,217.31 2,549.94 2,726.24 2,920.55 3,131.94 3,361.94 3,612.19 3,884.47 4,180.67 7.4%
Esoteric Testing 1,027.99 896.37 1,006.21 1,144.61 1,303.99 1,486.54 1,695.88 1,936.23 2,212.55 2,530.58 14.1%
Specialized Testing 578.69 526.27 577.26 642.37 716.65 800.81 896.30 1,004.82 1,128.31 1,269.04 12.0%
Noninvasive Prenatal
337.59 252.01 279.83 315.09 355.53 401.67 454.35 514.60 583.60 662.71 13.2%
Testing
Others 2,007.34 1,837.01 1,742.51 1,883.14 2,040.38 2,214.41 2,407.25 2,621.18 2,858.79 3,123.02 8.8%
The diagnostic labs market for the physiological function testing segment was worth US$ 3,596.15 million in 2021 and is projected to reach US$
7,432.70 million by 2028; it is expected to grow at a CAGR of 11.0% during the forecast period. The market for the esoteric testing segment is estimated
to be worth US$ 2,530.58 million by 2028 and is expected to grow at a CAGR of 14.1% during the forecast period.
72
10.1.5 Brazil: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD Million)
Table 3. Brazil Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million)
Physiological CAGR (2022–
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Function Testing 2028)
Endoscopy 1,253.79 1,096.65 1,187.63 1,305.04 1,437.93 1,587.17 1,755.01 1,944.05 2,157.26 2,398.08 10.7%
X-Ray 803.04 706.34 769.24 850.04 941.87 1,045.48 1,162.55 1,295.03 1,445.17 1,615.58 11.3%
CT 576.09 506.56 551.51 609.27 674.90 748.95 832.60 927.26 1,034.52 1,156.24 11.3%
ECG 436.95 383.94 417.71 461.12 510.42 565.99 628.74 699.69 780.03 871.14 11.2%
MRI 388.62 342.34 373.38 413.22 458.54 509.74 567.66 633.28 707.74 792.35 11.5%
Echo 134.53 118.97 130.26 144.71 161.18 179.84 201.00 225.04 252.38 283.53 11.9%
Others 2,811.59 2,464.53 2,674.79 2,945.66 3,252.75 3,598.29 3,987.67 4,427.07 4,923.65 5,485.69 10.9%
The diagnostic labs market for the others segment was worth US$ 2,674.79 million in 2021 and is projected to reach US$ 5,485.69 million by 2028; it
is expected to grow at a CAGR of 10.9% during the forecast period. The market for the echo segment is estimated to be worth US$ 283.53 million by
2028 and is expected to grow at a CAGR of 11.9% during the forecast period.
73
10.1.6 Brazil: Diagnostic Lab Market, by Revenue Source, 2019–2028 (USD Million)
Table 4. Brazil Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Revenue Source 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Healthcare Plan
5,154.04 5,595.18 6,060.91 6,662.04 7,342.78 8,107.73 8,968.58 9,938.73 11,033.68 12,271.30 10.7%
Operators and Insurers
Out-of-Pocket 3,179.22 3,431.49 3,695.72 4,038.87 4,425.91 4,858.80 5,343.66 5,887.50 6,498.34 7,185.43 10.1%
Public System 2,070.50 2,245.01 2,428.97 2,666.69 2,935.68 3,237.67 3,577.21 3,959.50 4,390.56 4,877.34 10.6%
The diagnostic labs market for the healthcare plan operators and insurers segment was worth US$ 6,060.91 million in 2021 and is projected to reach
US$ 12,271.30 million by 2028; it is expected to grow at a CAGR of 10.7% during the forecast period.
10.1.7 Brazil: Diagnostic Lab Market, by Cities, 2022 & 2028 (%)
Figure 37. Brazil: Diagnostic Lab Market, by Cities, 2022 & 2028 (%)
13.61% 14.22%
Sao Paulo
9.92% Rio de Janeiro 10.63%
2022 5.24% Salvador 2028

5.48%
4.15%
67.07% Brasilia 65.28% 4.39%
Other Cities
74
10.1.7.1 Sao Paulo: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
10.1.7.1.1 Overview
Major factors fueling the diagnostic lab market growth in Sao Paulo are the high prevalence of chronic diseases and the increasing use of point-of-care
diagnostics. The industry is booming with the growing number of patients being covered under the Universal Health System (SUS), increasing geriatric
population (above 65 years) and rising number of elderly patients with chronic diseases, and rising investments to raise the number of patients service
centers. According to NCBI (National Center of Biotechnology Information), the reported number of death cases due to the prevalence of
noncommunicable diseases (NCDs) among all other diseases caused the deaths in the country during the year 2018. These factors are estimated to
drive the growth of the diagnostic labs market in Sao Paulo during the forecast period.
10.1.7.1.2 Sao Paulo: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
The diagnostic labs market in the Sao Paulo is projected to grow from US$ 1,819.78 million in 2022 to US$ 3,460.30 million by 2028; it is expected to
grow at a CAGR of 11.3% during the forecast period.
Figure 38. Sao Paulo: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
3,460.30
3,095.23
2,773.52
2,489.61
2,238.70
2,016.62
1,819.78
1,646.55
1,511.66
2020 2021 2022 2023 2024 2025 2026 2027 2028
75
10.1.7.1.3 Sao Paulo: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million)
Table 5. Sao Paulo Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Lab Type 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Hospital-Based Labs 680.32 742.32 808.18 892.78 988.88 1,097.26 1,219.66 1,358.10 1,514.91 1,692.78 11.3%
Single/Independent
569.82 623.41 680.52 753.75 837.10 931.30 1,037.92 1,158.78 1,295.97 1,451.94 11.5%
Laboratories
Physician Office Labs 67.16 73.40 80.04 88.56 98.25 109.20 121.58 135.59 151.49 169.55 11.4%
Others 67.44 72.53 77.81 84.68 92.38 100.94 110.46 121.05 132.85 146.02 9.5%
The diagnostic labs market for the hospital-based labs segment was worth US$ 808.18 million in 2021 and is projected to reach US$ 1,692.78 million
by 2028; it is expected to grow at a CAGR of 11.3% during the forecast period. The market for the single/independent laboratories segment is estimated
76
10.1.7.1.4 Sao Paulo: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million)
Table 6. Sao Paulo Diagnostic Lab Market, by Testing Services– Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
2028)
500.31 440.35 481.06 533.24 592.66 659.86 735.96 822.28 920.33 1,031.86 11.6%
Testing
345.49 301.58 330.89 368.37 411.16 459.72 514.88 577.65 649.18 730.82 12.1%
Testing
COVID-19 Testing 14.26 305.96 359.77 386.21 415.34 447.04 481.53 519.04 559.84 604.17 7.7%
Esoteric Testing 136.95 119.27 135.94 156.91 181.27 209.43 242.02 279.78 323.57 374.40 15.6%
Specialized Testing 78.38 70.44 77.90 87.39 98.29 110.70 124.89 141.10 159.67 180.97 12.9%
43.76 32.65 36.90 42.26 48.47 55.63 63.89 73.43 84.46 97.23 14.9%
Testing
Others 265.59 241.41 224.07 245.39 269.43 296.32 326.45 360.23 398.17 440.84 10.3%
The diagnostic labs market for the physiological function testing segment was worth US$ 481.06 million in 2021 and is projected to reach US$ 1,031.86
million by 2028; it is expected to grow at a CAGR of 11.6% during the forecast period. The market for the esoteric testing segment is estimated to be
worth US$ 374.40 million by 2028 and is expected to grow at a CAGR of 15.6% during the forecast period.
77
10.1.7.1.5 Sao Paulo: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD Million)
Table 7. Sao Paulo Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million)
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Endoscopy 166.50 146.00 158.91 175.49 194.31 215.53 239.48 266.56 297.20 331.95 11.2%
X-Ray 106.77 94.14 103.03 114.42 127.40 142.10 158.77 177.71 199.26 223.81 11.8%
CT 76.15 67.24 73.69 81.94 91.36 102.04 114.17 127.96 143.67 161.59 12.0%
ECG 57.84 50.95 55.71 61.80 68.75 76.61 85.52 95.63 107.13 120.21 11.7%
MRI 51.28 45.38 49.85 55.56 62.09 69.50 77.94 87.55 98.51 111.03 12.2%
Echo 17.51 15.51 17.04 19.00 21.24 23.79 26.69 29.99 33.77 38.08 12.3%
Others 24.26 21.13 22.83 25.03 27.51 30.28 33.39 36.87 40.79 45.20 10.4%
The diagnostic labs market for the endoscopy segment was worth US$ 158.91 million in 2021 and is projected to reach US$ 331.95 million by 2028;
it is expected to grow at a CAGR of 11.2% during the forecast period. The market for the echo segment is estimated to be worth US$ 38.08 million by
78
10.1.7.1.6 Sao Paulo: Diagnostic Lab Market, by Revenue Source, 2019–2028 (USD Million)
Table 8. Sao Paulo Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Revenue Source 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Healthcare Plan
688.49 752.79 821.26 909.10 1,009.03 1,121.91 1,249.62 1,394.31 1,558.48 1,745.03 11.5%
Out-of-Pocket 417.50 454.39 493.43 543.69 600.66 664.77 737.01 818.53 910.65 1,014.91 11.0%
Public System 278.75 304.48 331.85 366.99 406.93 452.02 502.99 560.68 626.10 700.37 11.4%
The diagnostic labs market for the healthcare plan operators and insurers segment was worth US$ 821.26 million in 2021 and is projected to reach
79
10.1.7.2 Rio de Janeiro: Diagnostic Lab Market– Revenue and Forecast to 2028 (USD Million)
10.1.7.2.1 Overview
Rio de Janeiro holds a significant share of the diagnostic labs market in Brazil. The growth of the market in this city is primarily driven by increasing
demand for in vitro diagnostics (IVD) procedures (especially in recent years), the prevalence of infectious diseases, and awareness about diagnostic
tests. According to an article published by Oxford Academia, in 2017, Rio de Janeiro had an incidence rate of infectious diseases much higher than the
national average of 18.8 cases per 1000 live births. Such a high prevalence of infectious diseases is driving the growth of the diagnostic lab market in
Rio de Janeiro.
10.1.7.2.2 Rio de Janeiro: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
The diagnostic labs market in the US is projected to grow from US$ 1,326.51 million in 2022 to US$ 2,586.71 million by 2028; it is expected to grow at
a CAGR of 11.8% during the forecast period.
Figure 39. Rio de Janeiro: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
2,586.71
2,304.55
2,056.62
1,838.44
1,646.17
1,476.48
1,326.51
1,194.87
1,091.98
2020 2021 2022 2023 2024 2025 2026 2027 2028
80
10.1.7.2.3 Rio de Janeiro: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million)
Table 9. Rio de Janeiro Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Lab Type 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Hospital-Based Labs 494.73 541.75 591.87 656.05 729.07 811.58 904.94 1,010.74 1,130.79 1,267.23 11.6%
Single/Independent
410.40 451.10 494.67 550.37 613.92 685.96 767.73 860.69 966.53 1,087.19 12.0%
Laboratories
Others 41.52 45.33 49.37 54.56 60.45 67.09 74.58 83.04 92.62 103.47 11.3%
The diagnostic labs market for the hospital-based labs segment was worth US$ 591.87 million in 2021 and is projected to reach US$ 1,267.23 million
81
10.1.7.2.4 Rio de Janeiro: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million)
Table 10. Rio de Janeiro Diagnostic Lab Market, by Testing Services– Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
2028)
360.62 319.73 352.10 393.38 440.62 494.34 555.53 625.31 705.02 796.19 12.5%
Testing
248.21 217.74 239.97 268.32 300.78 337.71 379.80 427.83 482.72 545.54 12.6%
Testing
COVID-19 Testing 9.26 217.74 249.37 267.56 287.47 308.99 332.21 357.23 384.17 413.10 7.5%
32.36 24.13 27.27 31.24 35.84 41.15 47.29 54.40 62.63 72.17 15.0%
Testing
Others 191.76 174.61 170.42 187.90 207.70 229.97 255.04 283.30 315.20 351.28 11.0%
The diagnostic labs market for the physiological function testing segment was worth US$ 352.10 million in 2021 and is projected to reach US$ 796.19
82
10.1.7.2.5 Rio de Janeiro: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD Million)
Table 11. Rio de Janeiro Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million)
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Endoscopy 119.69 105.77 116.10 129.29 144.34 161.41 180.79 202.82 227.92 256.53 12.1%
X-Ray 76.74 68.16 75.19 84.16 94.43 106.13 119.48 134.72 152.16 172.14 12.7%
CT 55.07 48.94 54.03 60.51 67.95 76.42 86.09 97.14 109.79 124.29 12.7%
ECG 41.87 37.15 40.93 45.76 51.29 57.59 64.76 72.94 82.29 92.99 12.5%
MRI 37.11 33.00 36.44 40.83 45.87 51.61 58.16 65.66 74.24 84.08 12.8%
Echo 12.84 11.44 12.65 14.20 15.98 18.01 20.33 22.99 26.04 29.54 13.0%
Others 17.31 15.28 16.74 18.62 20.76 23.18 25.92 29.04 32.59 36.62 11.9%
The diagnostic labs market for the endoscopy segment was worth US$ 116.10 million in 2021 and is projected to reach US$ 256.53 million by 2028;
it is expected to grow at a CAGR of 12.1% during the forecast period. The market for the echo segment is estimated to be worth US$ 29.54 million by
83
10.1.7.2.6 Rio de Janeiro: Diagnostic Lab Market, by Revenue Source, 2019–2028 (USD Million)
Table 12. Rio de Janeiro: Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Revenue Source 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Healthcare Plan
495.53 544.47 596.86 663.83 740.23 826.80 925.04 1,036.69 1,163.77 1,308.62 12.0%
Out-of-Pocket 302.38 330.55 360.52 398.93 442.57 491.80 547.43 610.36 681.66 762.56 11.4%
Public System 197.73 216.95 237.49 263.75 293.69 327.57 365.97 409.56 459.12 515.53 11.8%
84
10.1.7.3 Salvador: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
10.1.7.3.1 Overview
Salvador is one of the hotspots of medical tourism in the world. Chronic kidney disease has reached epidemic levels in several Central American countries
from the early years of this century. According to MediGraphic, in 2020, chronic kidney disease was the second cause of death in men, the fifth in
persons with age 18 and above, and the third cause of hospital death in the adult population in El Salvador. Traditional risk factors such as diabetes
and high blood pressure are associated with chronic kidney diseases. These factors are linked with the growth of the diagnostic labs market in Salvador.
10.1.7.3.2 Salvador: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
The diagnostic labs market in the Salvador is projected to grow from US$ 700.46 million in 2022 to US$ 1,333.51 million by 2028; it is expected to
grow at a CAGR of 11.3% during the forecast period.
Figure 40. Salvador: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
1,333.51
1,192.59
1,068.43
958.87
862.06
776.39
700.46
633.65
581.62
2020 2021 2022 2023 2024 2025 2026 2027 2028
85
10.1.7.3.3 Salvador: Diagnostic Lab Market, by Lab Type – 2019–2028 (USD Million)
Table 13. Salvador Diagnostic Lab Market, by Lab Type– Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Lab Type 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Hospital-Based Labs 264.31 288.16 313.46 345.98 382.90 424.50 471.45 524.50 584.55 652.62 11.2%
Single/Independent
219.89 240.60 262.68 291.00 323.22 359.64 400.87 447.61 500.68 562.21 11.6%
Laboratories
Others 22.64 24.61 26.69 29.37 32.41 35.82 39.67 44.00 48.88 53.21 10.4%
The diagnostic labs market for the hospital-based labs segment was worth US$ 313.46 million in 2021 and is projected to reach US$ 652.62 million by
2028; it is expected to grow at a CAGR of 11.2% during the forecast period. The market for the single/independent laboratories segment is estimated
to be worth US$ 562.21 million by 2028 and is expected to grow at a CAGR of 11.6% during the forecast period.
86
10.1.7.3.4 Salvador: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million)
Table 14. Salvador Diagnostic Lab Market, by Testing Services – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
2028)
192.72 170.82 187.17 208.09 231.96 259.01 289.71 324.62 364.35 409.65 12.0%
Testing
132.48 115.10 126.37 140.78 157.23 175.90 197.13 221.30 248.85 280.30 12.2%
Testing
COVID-19 Testing 5.22 114.81 130.22 139.50 149.70 160.75 172.72 185.68 199.69 214.83 7.5%
17.15 13.14 14.72 16.72 19.03 21.68 24.73 28.23 32.27 36.94 14.1%
Testing
Others 102.91 94.45 92.96 101.88 111.94 123.21 135.85 150.02 165.96 183.89 10.3%
87
10.1.7.3.5 Salvador: Diagnostic Lab Market, by Physiological Function Testing – 2019–2028 (USD Million)
Table 15. Salvador Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million)
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Endoscopy 64.06 56.60 61.82 68.50 76.11 84.71 94.45 105.48 118.00 132.24 11.6%
X-Ray 40.97 36.40 39.97 44.53 49.75 55.67 62.40 70.07 78.82 88.81 12.2%
CT 29.33 26.09 28.68 31.99 35.78 40.08 44.98 50.57 56.94 64.23 12.3%
ECG 22.45 19.92 21.85 24.31 27.13 30.32 33.94 38.07 42.77 48.13 12.1%
MRI 19.77 17.60 19.36 21.61 24.19 27.12 30.46 34.26 38.61 43.59 12.4%
Echo 6.92 6.17 6.80 7.60 8.52 9.57 10.77 12.13 13.70 15.48 12.6%
Others 9.21 8.05 8.70 9.54 10.48 11.53 12.71 14.03 15.51 17.16 10.3%
The diagnostic labs market for the endoscopy segment was worth US$ 61.82 million in 2021 and is projected to reach US$ 132.24 million by 2028; it
88
10.1.7.3.6 Salvador: Diagnostic Lab Market, by Revenue Source – 2019–2028 (USD Million)
Table 16. Salvador Diagnostic Lab Market, by Revenue Source – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Revenue Source 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Healthcare Plan
264.90 289.75 316.23 350.18 388.82 432.49 481.90 537.89 601.45 673.69 11.5%
Out-of-Pocket 162.04 176.30 191.38 210.79 232.80 257.55 285.42 316.87 352.40 392.58 10.9%
Public System 105.74 115.57 126.05 139.49 154.77 172.03 191.55 213.66 238.74 267.23 11.4%
US$ 673.69 million by 2028; it is expected to grow at a CAGR of 11.5% during the forecast period.
89
10.1.7.4 Brasilia: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
10.1.7.4.1 Overview
Large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, and rapidly evolving technologies are
driving the growth of the market for molecular diagnostics in Brasilia. For instance, in November 2020, Chembio Diagnostics Brazil Ltda. received Agência
Nacional de Vigilância Sanitária (ANVISA) approval for the DPP SARS-CoV-2 Antigen test system. Chembio Diagnostics Brazil Ltda. is a subsidiary of
Chembio Diagnostics, Inc., a leading point-of-care diagnostic company focused on infectious diseases.
The use of molecular diagnostic techniques in the development and subsequent administration of personalized medicine is likely to boost the diagnostics
lab market growth in Brazil. For instance, in January 2022, the Oswaldo Cruz Foundation finished the development of two new molecular tests for the
diagnosis of COVID-19, including one test that has been submitted to ANVISA.
10.1.7.4.2 Brasilia: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
The diagnostic labs Market in the Brasilia is projected to grow from US$ 554.76 million in 2022 to US$ 1,068.27 million by 2028; it is expected to grow
at a CAGR of 11.5% during the forecast period.
Figure 41. Brasilia: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
1,068.27
953.63
852.76
763.88
685.44
616.11
554.76
500.83
458.76
2020 2021 2022 2023 2024 2025 2026 2027 2028
90
10.1.7.4.3 Brasilia: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million)
Table 17. Brasilia: Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Lab Type 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Hospital-Based Labs 207.92 227.19 247.68 273.98 303.86 337.59 375.70 418.84 467.74 523.24 11.4%
Single/Independent
173.45 190.21 208.11 231.02 257.13 286.69 320.19 358.23 401.47 450.70 11.8%
Laboratories
Others 17.40 18.94 20.57 22.67 25.05 27.72 30.73 34.13 37.97 42.30 11.0%
The diagnostic labs market for the hospital-based labs segment was worth US$ 247.68 million in 2021 and is projected to reach US$ 523.24 million by
2028; it is expected to grow at a CAGR of 11.4% during the forecast period. The market for the single/independent laboratories segment is estimated
to be worth US$ 450.70 million by 2028 and is expected to grow at a CAGR of 11.8% during the forecast period.
91
10.1.7.4.4 Brasilia: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million)
Table 18. Brasilia: Diagnostic Lab Market, by Testing Services – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
2028)
151.82 134.83 148.00 164.83 184.06 205.87 230.66 258.88 291.04 327.74 12.1%
Testing
104.36 90.51 99.66 111.34 124.70 139.90 157.21 176.95 199.50 225.30 12.5%
Testing
COVID-19 Testing 3.82 92.16 109.53 117.21 125.61 134.66 144.41 154.89 166.14 178.19 7.2%
13.79 10.46 11.69 13.26 15.06 17.14 19.52 22.26 25.41 29.06 14.0%
Testing
Others 80.88 73.31 67.32 74.47 82.60 91.78 102.15 113.88 127.19 142.29 11.4%
92
10.1.7.4.5 Brasilia: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD Million)
Table 19. Brasilia: Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million)
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Endoscopy 50.53 44.72 48.92 54.30 60.42 67.35 75.20 84.10 94.22 105.73 11.7%
X-Ray 32.22 28.69 31.57 35.26 39.47 44.27 49.73 55.96 63.08 71.22 12.4%
CT 23.17 20.61 22.66 25.27 28.27 31.67 35.54 39.95 44.98 50.73 12.3%
ECG 17.63 15.67 17.22 19.19 21.45 24.02 26.93 30.26 34.05 38.38 12.2%
MRI 15.62 13.92 15.34 17.14 19.21 21.56 24.24 27.30 30.80 34.81 12.5%
Echo 5.39 4.83 5.35 6.01 6.76 7.63 8.62 9.75 11.06 12.55 13.1%
Others 7.27 6.40 6.95 7.66 8.47 9.38 10.40 11.55 12.85 14.32 11.0%
The diagnostic labs market for the endoscopy segment was worth US$ 48.92 million in 2021 and is projected to reach US$ 105.73 million by 2028; it
93
10.1.7.4.6 Brasilia: Diagnostic Lab Market, Revenue Source, 2019–2028 (USD Million)
Table 20. Brasilia: Diagnostic Lab Market, Revenue Source – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Revenue Source 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Healthcare Plan
208.29 228.32 249.71 277.10 308.30 343.61 383.62 429.03 480.63 539.37 11.7%
Out-of-Pocket 127.79 139.32 151.54 167.24 185.05 205.11 227.74 253.29 282.19 314.92 11.1%
Public System 83.18 91.11 99.58 110.41 122.76 136.71 152.52 170.45 190.81 213.97 11.7%
US$ 539.37 million by 2028; it is expected to grow at a CAGR of 11.7% during the forecast period.
94
10.1.7.5 Other Cities: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
10.1.7.5.1 Overview
The growing prevalence of chronic, infectious, and other diseases; technological advancements in diagnostics tests; and the introduction of new
diagnostics instruments and diagnostics tests are fueling the growth of the diagnostics lab market in the Rest of Brazil. A rise in the geriatric population
is another factor supporting the growth of the market in this country.
10.1.7.5.2 Other Cities: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
The diagnostic labs Market in the Other Cities is projected to grow from US$ 8,968.10 million in 2022 to US$ 15,885.28 million by 2028; it is expected
Figure 42. Other Cities: Diagnostic Lab Market – Revenue and Forecast to 2028 (USD Million)
15,885.28
14,376.59
13,034.40
11,838.64
10,771.84
8,966.10
9,818.76
8,209.71
7,627.67
2020 2021 2022 2023 2024 2025 2026 2027 2028
95
10.1.7.5.3 Other Cities: Diagnostic Lab Market, by Lab Type, 2019–2028 (USD Million)
Table 21. Other Cities: Diagnostic Lab Market, by Lab Type – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Lab Type 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Hospital-Based Labs 3,525.11 3,792.39 4,071.01 4,434.33 4,843.16 5,299.15 5,808.43 6,378.02 7,015.93 7,731.37 9.7%
Single/Independent
2,919.80 3,158.70 3,409.67 3,734.68 4,101.73 4,512.92 4,974.20 5,492.41 6,075.39 6,732.18 10.3%
Laboratories
Others 286.39 309.09 332.86 363.72 398.53 437.46 481.04 529.92 584.81 646.53 10.1%
The diagnostic labs market for the hospital-based labs segment was worth US$ 4,071.01 million in 2021 and is projected to reach US$ 7,731.37 million
96
10.1.7.5.4 Other Cities: Diagnostic Lab Market, by Testing Services, 2019–2028 (USD Million)
Table 22. Other Cities: Diagnostic Lab Market, by Testing Services – Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
2028)
2,566.22 2,244.06 2,427.82 2,665.17 2,933.60 3,234.78 3,573.20 3,953.98 4,383.06 4,867.25 10.6%
Testing
1,755.13 1,507.99 1,636.81 1,802.63 1,990.51 2,201.76 2,439.65 2,707.90 3,010.82 3,353.38 10.9%
Testing
COVID-19 Testing 62.23 1,486.63 1,701.05 1,815.76 1,942.43 2,080.50 2,231.08 2,395.35 2,574.64 2,770.39 7.3%
Esoteric Testing 699.37 607.93 678.12 766.60 867.98 983.47 1,115.20 1,265.64 1,437.66 1,634.60 13.5%
230.53 171.62 189.23 211.60 237.12 266.06 298.93 336.29 378.82 427.31 12.4%
Testing
Others 1,366.20 1,253.23 1,187.74 1,273.51 1,368.70 1,473.13 1,587.77 1,713.74 1,852.27 2,004.72 7.9%
The diagnostic labs market for the physiological function testing segment was worth US$ 2,427.82 million in 2021 and is projected to reach US$
4,867.25 million by 2028; it is expected to grow at a CAGR of 10.6% during the forecast period. The market for the esoteric testing segment is estimated
97
10.1.7.5.5 Other Cities: Diagnostic Lab Market, by Physiological Function Testing, 2019–2028 (USD Million)
Table 23. Other Cities: Diagnostic Lab Market, by Physiological Function Testing – Revenue and Forecast to 2028 (USD Million)
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Endoscopy 853.01 743.56 801.88 877.46 962.74 1,058.17 1,165.10 1,285.09 1,419.92 1,571.64 10.2%
X-Ray 546.35 478.96 519.47 571.68 630.82 697.31 772.17 856.56 951.86 1,059.60 10.8%
CT 392.38 343.69 372.45 409.55 451.55 498.73 551.82 611.64 679.13 755.40 10.7%
ECG 297.17 260.26 282.00 310.05 341.80 377.46 417.59 462.79 513.79 571.42 10.7%
MRI 264.83 232.43 252.38 278.07 307.18 339.94 376.85 418.51 465.58 518.85 11.0%
Echo 91.87 81.04 88.43 97.90 108.67 120.84 134.59 150.16 167.82 187.88 11.5%
Others 120.61 104.12 111.19 120.47 130.84 142.33 155.08 169.23 184.97 202.48 9.0%
The diagnostic labs market for the others segment was worth US$ 801.88 million in 2021 and is projected to reach US$ 1,571.64 million by 2028; it is
expected to grow at a CAGR of 10.2% during the forecast period. The market for the echo segment is estimated to be worth US$ 187.88 million by 2028
and is expected to grow at a CAGR of 11.5% during the forecast period.
98
10.1.7.5.6 Other Cities: Diagnostic Lab Market, Revenue Source– 2019–2028 (USD Million)
Table 24. Other Cities: Diagnostic Lab Market, Revenue Source– Revenue and Forecast to 2028 (USD Million)
CAGR (2022–
Revenue Source 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
2028)
Healthcare Plan
3,496.83 3,779.85 4,076.85 4,461.83 4,896.40 5,382.93 5,928.40 6,540.81 7,229.35 8,004.59 10.2%
Out-of-Pocket 2,169.52 2,330.93 2,498.85 2,718.22 2,964.83 3,239.57 3,546.07 3,888.45 4,271.44 4,700.45 9.6%
Public System 1,405.09 1,516.89 1,634.01 1,786.05 1,957.53 2,149.34 2,364.18 2,605.14 2,875.80 3,180.23 10.1%
The diagnostic labs market for the healthcare plan operators and insurers segment was worth US$ 4,076.85 million in 2021 and is projected to reach
99
11. Impact Of COVID-19 Pandemic on Brazil Diagnostic
Lab Market
11.1 Brazil: Impact Assessment of COVID-19 Pandemic
Brazil has been grappling with serious issues related to governance, economy, and insufficient healthcare capacity. Moreover, continuous demand for
the treatment of vector-borne diseases and community-acquired infections, and high rates of noncommunicable diseases have been overburdening
hospitals and clinics in these countries.
Weak social protection, fragmented health systems, and profound inequalities exacerbated the ill effects of the COVID-19 pandemic in Brazil. The
pandemic has hampered supply and demand equations in different industries, including healthcare and tourism; it also limited household earnings and
private consumption. The government in Brazil acted quickly and predictably to safeguard their populations as well as to control the progress of COVID-
19 and its economic consequences. However, the country failed to keep the case count under control due to the prevalence of an informal economy,
and the limitations of health infrastructure and social protection mechanisms. On the other hand, governments ramped up the capacities of their
healthcare systems to deal with the crisis, allowing better access to health to people.
The COVID-19 pandemic has demonstrated the criticality of health in the social and economic growth, reinforcing the need for greater health investments
to secure people's wellbeing and build long-term health systems in Brazil. According to a study published in August 2020 in the Journal of the American
College of Radiology, the scenario in this country is similar to that experienced in the US: there were reports of substantial drops in the demand for
diagnostic imaging services across the country, with a 56.4–63.7% reduction among inpatients. Despite these numbers, the demand for diagnosis of
diseases remained high at many facilities handlings COVID-19-related emergencies, which require examinations such as X-ray and computed tomography
(CT) for the detailed diagnosis of the disease, as well as for monitoring its progression and lung involvement. Thus, diagnostic centres that already
100
adopted picture archiving and communication systems had an edge over competitors as the systems promote agility and improve the ability of visualizing
the affected areas, serving as support for more assertive decision-making regarding the diagnosis.
Figure 43. Impact Of COVID-19 Pandemic in Brazil Market
Assessment of Regional Impact
Brazil
Low Impact High Impact
101
12. Brazil Diagnostic Labs Market–Industry Landscape
12.1 Overview
The developments done by the companies in the market have been characterized as organic and inorganic developments. Various companies are
focusing on organic strategies such as expansion. Inorganic growth strategies witnessed in the market were acquisitions, and partnerships. These growth
strategies have aided the market players in the expansion of their business and enhance their geographic presence. Additionally, growth strategies such
as acquisitions and partnerships helped in strengthening their customer base and increase the product portfolio.
The companies have maximized their growth with several inorganic strategies to enhance the market value and position in the market. The organic
developments hold 10.00% of the total strategic developments in the market. Whereas the inorganic strategies helped by 90.00% for the growth of the
companies.
102
12.2 Growth Strategies Done by the Companies in the Market (%)
Figure 44. Growth Strategies Done by the Companies in the Market (%)
103
12.3 Organic Developments
12.3.1 Overview
During the year 2018 to 2021, various companies have made organic growth strategies in the market there are operating. Some of the activities
undertaken by the company, which have promoted its growth are, product launches, product approvals and others. Companies such as Dasa Labs,
Quest Diagnostics Incorporated, SYNLAB-Solutions in Diagnostics, Grupo Fleury, Hospital Israelita Albert Einstein, and Hermes Pardini has been
implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The
companies have utilized strategies such as product launch, product up-gradation, patents, expansion of their product portfolio and area expansion for
the growth of their organizations. In addition, the companies have invested their efforts to develop products and have received approvals from regulatory
bodies such as US FDA for their products.
Table 25. Organic Developments Done by Companies

Month & Year Company Growth Type Description
Quest Diagnostics, the world's leader in diagnostic
information services announced the availability of an
Jan-2022 Quest Diagnostics Incorporated Product Launch at-home COVID-19 rapid antigen test service for
consumer purchase available through "QuestDirect" a
consumer-initiated testing platform.
104
12.4 Inorganic Developments
12.4.1 Overview
Inorganic developments made by the companies that are operating in the Brazil Diagnostic Labs market have are acquisitions, and agreements between
companies. Companies such Dasa Labs, Quest Diagnostics Incorporated, SYNLAB-Solutions in Diagnostics, Grupo Fleury, Hospital Israelita Albert
Einstein, and Hermes Pardini have been implementing various inorganic developments that have bought about dynamic improvements in the market
they are operating. Due to the involvement of major players which has led to availability of better services and products in the market.
Table 26. Inorganic Developments Done by Companies

Month & Year Company Growth Type Description
HalioDx SAS, the immuno-oncology diagnostic company announced signing of a
distribution agreement with DASA for new product commercialization "Immunoscore"
Dec-2020 Dasa Labs Partnership
a unique diagnostic assay for predicting the risk of recurrence and the response to
chemotherapy regimen of patients with early stage colon cancer.
Dasa, the largest integrated healthcare network in Brazil announced expanding

partnership with SOPHiA GENETICS SA. The partnership will offer the first
decentralized Homologous Recombination Deficiency (HRD) analytics solution in
Aug-2020 Dasa Labs Partnership
Latin America. The partnership further evolves when DASA implemented SOPHiA
DDMTM Radiomics and Trial Match solutions in 2020 to create the first multimodal
approach in the region.
GRAIL, Inc., a healthcare company announced agreement with Quest Diagnostics, a

Feb-2021 Quest Diagnostics Incorporated Collaboration leading provider of diagnostic information service, offering support for GRAIL's
multicancer early detection blood test.
eMed, a telehealth company announced collaboration with Quest Diagnostics a

world's leading provider of diagnostic information services, for bringing clinician-
guided rapid antigen testing for COVID-19 employers seek faster safer environment
Aug-2021 Quest Diagnostics Incorporated Collaboration
by decreasing the risk of COVID-19 exposure at workplaces. Through such
collaboration the two companies will leverage the BinaxNOW COVID-19 Ag Card
Home Test, a self-administered, nasal swab antigen offering results in 15 minutes.
105
SYNLAB, Europe’s leading medical diagnostic services provider announced
partnership with International Air Transport Association (IATA) to facilitate safe and
Aug-2021 SYNLAB - Solutions in Diagnostics Partnership
easy travel. The two partners signed an agreement that incorporate SYNLAB's
extensive lab network into IATA Travel Pass.
SYNLAB announced collaboration with genomic and theranostic firm "OncoDNA" for
offering the OncoDeep biomarker test for cancer therapy selection in Germany.
Mar-2022 SYNLAB - Solutions in Diagnostics Collaboration Through this collaboration, SYNLAB in Germany will have access to the OncoDeep
test for performing comprehensive testing of solid tumors and offer support for
oncologists.
Sweetch, a digital therapeutics innovator announced partnership with Grupo Fleury

one of Brazil's leading healthcare providers. The partnership aims Fleury to
Sep-2021 Grupo Fluery Partnership
implement " Saúde iD telemedicine" services to improve healthcare outcomes for
patients living with chronic conditions as part of substantial multi-year contract.
City of Hope, a world-renowned independent research and treatment center for

cancer and diabetes announced expansion of its leading-edge cancer expertise to
South America through an education agreement with Hospital Israelita Albert
Apr-2021 Hospital Israelita Albert Einstein Partnership Einstein, a top cancer center in Latin America. The three-year agreement calls for City
of Hope to share its specialized cancer expertise with Hospital Israelita Albert
Einstein’s oncology residents and clinical staff. Both institutes will explore potential
innovative collaborations in precision oncology and research.
Siemens Healthineers announced collaboration with Hermes Pardini for transforming

in-vitro diagnostic care delivery by developing "The Enterprise Project" in Minas
Gerias, Brazil. The Enterprise Project is largest and most complex clinical analysis
laboratory known to date and is expected to be capable of handling 110 million
Apr-2018 Hermes Pardini Collaboration
sample tubes annually upon completion. Additionally, the Enterprise Project delivers
a 3D view of the laboratory configuration, enabling operators to manage alerts,
control instruments, and reagent monitoring remotely and observe test progression
in real time.
106
13. Company Profiles
13.1 Dasa Labs
13.1.1 Key Facts
Dasa Labs
Founded 2019
Corporate Address Rajeshwari Altius, 19th Cross, Ideal Homes Layout, RR Nagar, Bengaluru, Karnataka
URL www.dasalabs.com
Location Global
Number of Employees 10
13.1.2 Business Description

Digital Assisted, Sensibly Augmented (DASA) company comprises technologists and healthcare specialists who are highly driving towards accuracy in
diagnosis, assisting patients suffering from life-threatening lung diseases. DASA Labs has partnerships with leading academic medical centers, large
global hospitals, and diagnostic centers, involving leading radiologists, pulmonologists, and data science experts. Additionally, DASA labs use Artificial
Intelligence (AI) that provides deep insights into any disease by application of deep learning algorithms for finding patterns in a carefully selected, large
number of high-resolution CT scans.
107
13.1.3 Products and Services
Product Category Product Name Description
Dasa created "Genov" a scientific project of genomic surveillance
for sample sequencing amid COVID-19 pandemic standing as
the main purpose of tracking the genetic evolution of SARS-CoV-
Diagnostics • Genov
2 in real time is Brazil was amid pandemic. 30 thousand
complete coronavirus genomes can be sequenced in upto 12
months.
Dasa Empresas provides benefits advisory solutions, health

coordination, and business solutions, such as occupational
• Outpatient Care, Diagnostics, and Care Coordination health. Dasa's care coordination unit possess over 20 years of
• Dasa Empresas experience in healthcare sector and has +150,000 lives under
Services
• Care Coordination management. The main competitive advantage of Dasa lies in
• Dasa Genomics an innovative model encompassing primary, secondary, tertiary
care, offering an efficient and quality assistance to users
through integrated care.
Nav is Dasa's health digital platform that connects both patients

and physicians through an intuitive and data-based experience.
Digital Platform • Nav Additionally, Nav offers a convenient and simple experience
through scheduling services, telemedicine, and access to test
results.
13.1.4 Financial Overview

The company is privately held; therefore, no financials are available in the public domain.
108
13.1.5 SWOT Analysis
S W O T
STRENGTH WEAKNESSES OPPORTUNITIES THREATS
• The company is • The company facing • The company may pursue • The emergence of new
encompassed in patent infringement inorganic growth players in developed, as
diagnostics systems. The issues with various strategies for expanding well as developing nations
company is also offering a medical devices such as its business. Also, the can offer stiff competition
broad range of products in diagnostic equipment’s. company is in the process for the company.
the field of diagnostics Such issues stand as of expanding its business Moreover, the pricing
market. The company is biggest weakness and through online distribution policies of local players
offering artificial may result in litigation channels for have the potential to
intelligence to offer that can affect the brand strengthening its hamper the adoption of
deeper insights of any image and the revenue geographic footprints. diagnostic systems of the
disease, by applying deep generation of the company creating a threat
learning algorithms in a company. for the competitive
selected, large number of players.
high-resolution CT scans.
Additionally, provides a
longitudinal view for
progress tracking.
Source: Press Release, Newsletters, and Company Annual Report
109
13.1.6 Key Developments
Date Development Category Description
HalioDx SAS, the immuno-oncology diagnostic company announced signing of
a distribution agreement with DASA for new product commercialization
HalioDx Partners with DASA, the Largest
Dec-2020 Partnership "Immunoscore" a unique diagnostic assay for predicting the risk of recurrence
Diagnostics Provider in Latin America
and the response to chemotherapy regimen of patients with early stage colon
cancer.
Dasa, the largest integrated healthcare network in Brazil announced

expanding partnership with SOPHiA GENETICS SA. The partnership will offer
Dasa expands partnership with SOPHiA
the first decentralized Homologous Recombination Deficiency (HRD) analytics
Aug-2020 GENETICS for the first decentralized cancer Partnership
solution in Latin America. The partnership further evolves when DASA
biomarker detection solution in Latin America
implemented SOPHiA DDMTM Radiomics and Trial Match solutions in 2020
to create the first multimodal approach in the region.
110
13.2 Quest Diagnostics Incorporated
13.2.1 Key Facts
Quest Diagnostics Incorporated
Founded 1990
Corporate Address 500 Plaza Drive Secaucus, NJ 07094
Telephone 973-520-2700
URL www.questdiagnostics.com
Location Global
Exchange Ticker Symbol NYSE: DGX
Fiscal Year End Dec-2021

Quest Diagnostics Incorporated is among the leading provider of diagnostic information services. The company provides services including advanced
diagnostics, general diagnostics, and other diagnostics services to improve health outcomes. Moreover, the Quest Diagnostics is the first national
diagnostic information services provider that majorly focuses on consumer interests to deliver patient connectivity solutions and also offers on-line
patient appointment scheduling. The company operates its business in 2 major segments, including diagnostic solutions and diagnostic information
services. The diagnostic information services (DIS) segment offers services including gene-based & esoteric (including advanced diagnostics) testing
services, routine clinical testing services, anatomic pathology testing services, and others. The company provides noninvasive prenatal screening. The
company offers a wide range of tests recommended during pregnancy. The company expands its diagnostic solutions through partnerships with
academic institutions, research & development activities, healthcare leaders, and other public health agencies.
111
Quanum Practice Solutions is a suite of complementary software solutions and services
helping to improve clinical decisions, streamlining practice management, and connect
providers across care settings for supporting continuity of care. Additionally, Quanum
Practice Solutions combines a powerful electronic health record platform with a
• Quanum Practice Solutions comprehensive revenue cycle management solution and robust patient engagement tool.
Quest Diagnostics has wide range of specimen validity testing. With specimen validity
Practice Solutions • Specimen Validity Testing
testing the company ensures the integrity of the test by measuring ph, creatinine, specific
• Oral Fluid Testing gravity, and testing adulterants that may be added in urine specimen. Quest Diagnostic's
oral fluid testing offers accurate results after a simple collection. Oral fluid testing offers a
confidential lab-based results. On utilization, donors can collect their own specimens on-
site and in the presence of a monitor, reducing the likelihood of tampering or a donor
challenge later in the drug specimen process.
112
ANNUAL REVENUE ($ MN)
12000 10788
10000 9437
7726
8000
6000
4000
2000
0
2019 2020 2021
113
REVENUE BY BUSINESS SEGMENT, 2020(%)
6.00%
Diagnostic Information Services
Diagnostic Solutions
94.00%
114
S W O T
• Quest Diagnostics has • The company exposed to • With pressure to • Quest Diagnostics has no
strengthened governmental litigations healthcare costs poses a assurance of
relationships with health and legal proceedings risk for the company, it precautionary measures
plans and has increased with regards to possible also creates opportunities for preventing, containing,
the volume of services for anticompetitive market for increasing proper or successfully defending
members by focusing on practices acts as a biggest utilization of testing acting cybersecurity or
driving value and weakness. Such factors as an efficient means for information security
providing a strong value may result in disturbing managing the total cost of threats having a
proposition for members financial position and healthcare. Also, the significant impact on
and clinicians. operations resulting in company creates greater business, resulting in
Additionally, Quest adverse outcome for the opportunities for operations and reputation
Diagnostics has core company. consolidation and gaining being subject to liability
strength in quality, assets, considerable share for
and capabilities in high-value, lower-cost
delivering value, providers as compared to
innovation, and other providers
collaboration. For
example, Quest
Diagnostics has been
chosen by
UnitedHealthcare as a
participant in the
UnitedHealthcare
Preferred Lab Network,
reflecting the strength of
the company.
115
Quest Diagnostics, the world's leader in diagnostic information services
Quest Diagnostics Launches COVID-19 Rapid announced the availability of an at-home COVID-19 rapid antigen test service
Jan-2022 Product Launch
Antigen Test for consumer purchase available through "QuestDirect" a consumer-initiated
testing platform.
eMed, a telehealth company announced collaboration with Quest Diagnostics

a world's leading provider of diagnostic information services, for bringing
eMed™ and Quest Diagnostics Collaborate to clinician-guided rapid antigen testing for COVID-19 employers seek faster
Aug-2021 Offer Guided COVID-19 Rapid Antigen Testing to Collaboration safer environment by decreasing the risk of COVID-19 exposure at
Help Employers Foster Safer Workplaces workplaces. Through such collaboration the two companies will leverage the
BinaxNOW COVID-19 Ag Card Home Test, a self-administered, nasal swab
antigen offering results in 15 minutes.
GRAIL and Quest Diagnostics Announce GRAIL, Inc., a healthcare company announced agreement with Quest
Feb-2021 Collaboration to Support Galleri, First-of-Kind Collaboration Diagnostics, a leading provider of diagnostic information service, offering
Multi-Cancer Early Detection Blood Test support for GRAIL's multicancer early detection blood test.
116
13.3 SYNLAB - Solutions in Diagnostics
13.3.1 Key Facts
SYNLAB - Solutions in Diagnostics
Founded 1998
Corporate Address Moosacher Straße 88 80809 Munich, Germany
Telephone +49 89 3076020
URL www.synlab.com
Location Global
Fiscal Year End Mar-2021

SYNLAB builds the activities on medical expertise and scientific leadership. SYNLAB offers a full spectrum of testing, from routine to highly specialized
tests. More than 1,500 tests have been developed in-house, and over 300 medicals were co-authored by experts of the Group in the last year.
Additionally, SYNLAB Group has established a proprietary medical community network by maintaining numerous partnerships with universities.
Moreover, an organic portfolio of more than 5,000 tests and a network of medical excellence of more than 2,000 medical experts and cooperation's
with universities and research institutes make SYNLAB Group the No.1 for specialty testing in Europe. Every year, SYNLAB provides millions of patients
and tens of thousands of health professionals accounting for more than 600 million tests generating results. Further, SYNLAB Group has successfully
closed and integrated more than 120 acquisitions resulting in its international footprint in eight additional countries.
117
SYNLAB offers highly efficient diagnostic services with cutting-edge technologies in over
500 SYNLAB laboratories and 1800 blood collecting units. The company also offers
Diagnostics • Medical Diagnostics
personal consultation and interpret results, creating a solid foundation in delivering
effective therapy.
4500
3973.51
4000
3500
3000 2766.44
2500
2011.72
2000
1500
1000
500
0
2019 2020 2021
118
REVENUE BY GEOGRAPHY, 2021(%)
15.00%
North and East
30.00%
South
18.00%
France
Germany
37.00%
119
S W O T
• SYNLAB is a pioneer in the • The company has to work • SYNLAB pursues several • Constantly changing
European clinical on effective product growth opportunities regulatory environment
laboratories market demand forecasting as it through efficient capital can pose significant
consolidation trend. The has higher rate of missed deployment, investments threats for diagnostic
company's expansion opportunities as in business, and selective laboratory business.
strategy is focused on compared to competitors. acquisitions in current Liability of laws and
adapting to the local and new markets. changing taxation policies
market environment with Additionally, as of June hamper the sales of
strength from its pan- 2021, the Group has products and services to
European support remarkable market cap of some extent.
functions. SYNLAB's US$15 bilion among the
market position and the European region with
scale of its laboratory US$13 billion from
network allow SYNLAB to emerging and other
benefit from favorable markets and US$4 billion
procurement conditions globally creating new
with suppliers, including market opportunities
Group-wide pan-European arising from precision
framework supply medicine, D2C offerings,
agreements for reagents and artificial intelligence.
and equipment. SYNLAB is
a leading provider of
healthcare services in the
Emila Romagna region
that has to strengthen the
company's number one
position in Italy.
120
SYNLAB announced collaboration with genomic and
theranostic firm "OncoDNA" for offering the OncoDeep
biomarker test for cancer therapy selection in
Synlab and OncoDNA partner to offer cancer
Mar-2022 Collaboration Germany. Through this collaboration, SYNLAB in
therapy testing in Germany
Germany will have access to the OncoDeep test for
performing comprehensive testing of solid tumors and
offer support for oncologists.
SYNLAB, Europe’s leading medical diagnostic services

provider announced partnership with International Air
SYNLAB and IATA partner to facilitate safe Transport Association (IATA) to facilitate safe and easy
Aug-2021 Partnership
and easy travelling travel. The two partners signed an agreement that
incorporate SYNLAB's extensive lab network into IATA
Travel Pass.
121
13.4 Grupo Fluery
13.4.1 Key Facts
Grupo Fluery
Founded 1926
Corporate Address Sau Paulo, Brazil
URL www.fleury.com
Location Europe, Global
Fiscal Year End Sep-2020

Since its inception, Grupo Fleury has been driving a passion for medicine, and the organization is one of the most respected medical and healthcare
organizations in Brazil. Groupo Fleuro has approximately 216 service units under the brands Fluery Medicina e Saúde, a+ Medicina Diagnóstica,
Laboratório Weinmann, Labs a+, Clínica Felippe Mattoso, Diagnoson a+, Weinmann Serdil, Instituto de Radiologia, Campana, Cedire, Centro de Patologia
Clínica, Diagmax, LAFE, Inlab, Papaz and SantéCorp. Through these brands Groupo Fleuro is present in markets of São Paulo, Rio de Janeiro, Rio Grande
do Sul, Paraná, Bahia, Pernambuco, Rio Grande do Norte, Distrito Federal and Maranhão. Additionally, Grupo Fleuro partners with several renowned
hospitals for carrying out diagnoses, both clinical and imaging analysis with other specialties, offering diagnostic information of high added value for the
condition of work of doctors.
122
450 445.39
440
430
420 416.75
409.74
410
400
390
2018 2019 2020
123
REVENUE BY BUSINESS SEGMENT, 2020(%)
30.00%
Diagnostic Medicine
Integrated Medicine
70.00%
124
S W O T
• Grupo Fluery has • The company has • Grupo Fleury has a • Heightened competition
consistently been witnessed declining continuous focus on from technological
engaged in the research revenues in previous inorganic growth innovations in the has
and development years. Such declining strategies, that has created competitiveness
activities acting as a core revenues might restrict helped the company to in diagnostic labs market.
strength for the company. the Grupo Fleuro to achieve a strong market Some countries also
Also, its revenues have restrict the company's position. The company forcing localizations as a
been increasing owing to ability to spend has an opportunity to component of their
strong sales in medical significantly on R&D and continue its focus on economic policies posing
diagnostic systems. The business expansion inorganic growth a threat for the company's
medical diagnostics strategies. Therefore, strategies resulting in overall growth.
system increase revenue such declining revenues expansion of diagnostic
owing to strong sales in would weaken the labs business.
CT, MRI, and other position of the Grupo
medical diagnostic Fleury.
solutions.
125
Sweetch, a digital therapeutics innovator
announced partnership with Grupo Fleury one of
Sweetch Enters Strategic Partnership with Grupo Brazil's leading healthcare providers. The
Sep-2021 Fleury's Saúde iD to Tackle Brazil's Chronic Partnership partnership aims Fleury to implement " Saúde iD
Disease Prevalence Amidst COVID-19 Pandemic telemedicine" services to improve healthcare
outcomes for patients living with chronic conditions
as part of substantial multi-year contract.
126
13.5 Hospital Israelita Albert Einstein
13.5.1 Key Facts
Hospital Israelita Albert Einstein
Founded 1955
Corporate Address Brazil
Telephone +55 11 2151-1233
URL www.einstein.com
Location Global

Einstein is a complete health system operating in health promotion, prevention, diagnosis, treatment, care coordination, management, teaching,
research, and many others. Further, in the last few years, Einstein has accelerated digital transformation through self-service, and remote interactions
through telemedicine have made it easier for patients to seek information, get healthcare support, and schedule appointments with all the speed and
convenience that the online model offers.
127
Cardiologia Einstein is structured to guarantee the
management of protocols and the best indicators of
quality of exams and procedures performed. For
• Diagnostic Cardiology example, echocardiogram sector is equipped with
• Guided Intervention Center by Picture advanced equipment for performing tests such as
three-dimensional and three-dimensional strains
• Endoscopy
Einstein Diagnostics echocardiograms. The Einstein Image Guided
• Image
Intervention Center is the largest and most complete
• Laboratory Center for Interventional Radiology and Oncology
• Clinical Neurophysiology Intervention in Brazil, equipped with advanced
technological resources and arranged in a single
physical area, entirely dedicated to minimally
invasive practices.

128
S W O T
• Global presence of • The company has • The company has limited • In the global market, there
Hospital Israelita Albert restricted business presence in international are a large number of
Einstein can act as one of outside the Brazilian markets. The company companies that lead the
the key strength of the market. Whereas the has active business diagnostic labs markets.
company as it determines international market has partnership; and these These companies have a
business reach to more significant potential partnerships can help the strong foothold with the
targeted market and for business development company to explore help of substantial
ensure easy availability and expansion. Such business opportunities in businesses operations
factors can act as a the worldwide market. The with use of advanced
biggest weakness for the worldwide market has technologies. Such factors
company's growth in the possibly huge potential to offer a very attractive
near future. expand the company service offerings in terms
business in emerging of cost and technological
regions involving APAC, customizations. However,
the Middle East, and as the company has
Africa. limited business outside
Brazil market, it acts as
one of the core threats for
the company's growth.
129
City of Hope, a world-renowned independent
research and treatment center for cancer and
diabetes announced expansion of its leading-edge
cancer expertise to South America through an
education agreement with Hospital Israelita Albert
City of Hope and Hospital Israelita Albert
Einstein, a top cancer center in Latin America. The
Apr-2021 Einstein Sign Agreement to Advance Cancer Partnership
three-year agreement calls for City of Hope to share
Care in Latin America
its specialized cancer expertise with Hospital
Israelita Albert Einstein’s oncology residents and
clinical staff. Both institutes will explore potential
innovative collaborations in precision oncology and
research.
130
13.6 Alliar
13.6.1 Key Facts
Alliar
Founded 2011
Corporate Address Sao Paulo/SP Alameda Vicente Pinzon, 51
Telephone +(11) 5088-1050
URL www.alliar.com
Location Global
Fiscal Year End Dec-2020

Allier has a core presence in ten Brazilian states, bringing excellence to the Brazilian population. Since its inception, Allier has been one of the country's
largest and most renowned health diagnostic systems, with a presence in 43 cities in 10 Brazilian states, totaling more than 120 strategically distributed
service units. Additionally, Alliar Médicos à Frente has the most modern technological park in the high-complexity diagnostic medicine segment, standing
as the second-largest company in the market in terms of magnetic resonance equipment, tomography, and ultrasound scanners with massive
investments in the importation of technologies. Further, in 2011 alone, Alliar was one of the world's most significant medical equipment purchases
involving High Field Magnetic Resonance, Multislice Tomography, and PET-CT.
131
The imaging exams include the capture of images and
their subsequent interpretation by a qualified
physician to issue a medical report. Some examples:
magnetic resonance, computed tomography,
ultrasound, x-rays, bone densitometry, mammography,
scintigraphy, PET-CT (positron emission tomography -
• Diagnostic Imaging
Diagnostic Medicines computed tomography), among others. The exams of
• Clinical Analysis
clinical analysis concern the collection of samples and
their subsequent analysis by a qualified professional,
using automated equipment. Some examples: blood
count, cholesterol, triglycerides, urinalysis 1, stool
test, detection of sexually transmitted diseases,
pathology, among others.
132
225 221.87 220.98

220
215
210
205
200
195 190.76
190
185
180
175
2018 2019 2020
133
S W O T
• Alliar has widespread • The company is involved • The company has a broad • The company has a
network of distribution in various businesses scope of opportunities in potential threat from
partners in the Brazil. globally thus having a high terms of long-term various scenarios such as
Also, the company has susceptibility to changes demand growth for larger foreign exchange
strong network of in the economic diagnostic labs business rates movements that
distributors that can reach conditions of a particular and development in largely governs the
maximum end users. Such region and countries. The emerging countries, company revenue
factors result in gaining a company faces difficulty in increased demand for generation from
strong foothold over the the management of digitization in the worldwide business
regional market. Further, increased manufacturing healthcare research field operations. The delayed
Alliar also benefits to and sales costs for offers significant execution of government
provide quick post-sales specific product acting as opportunities. budgets and budget cuts
services to the customers strong weakness for in various countries also
acting as strength for the company's overall growth impacts the company's
overall company's growth. business planning.

There are no recent developments for Alliar in the Brazil diagnostic labs market.
134
13.7 Boris Berenstein Diagnostic Center
13.7.1 Key Facts
Boris Berenstein Diagnostic Center
Founded 1988
Corporate Address R. Ribeiro de Brito, 590 - Boa Viagem, Recife - PE, 51021-310, Brazil
Telephone +81 32161900
URL www.boris.com
Location Global

Boris Berenstein Diagnostic Center has made a remarkable contribution to the field of activity, starting from several imaging services in a single place,
differentiated working hours, and units locality in the primary and commercial centers of the Metropolitan Region of Recife, offering more comfort and
convenience for the patients. Additionally, Boris Berenstein achieved first place in the surveys of most remembered brands in the diagnostic imaging
category. Such work has been reflected in the achievement of brand recognition brands annually held by three primary communication vehicles in the
State of Pernambuco. Further, Boris Berenstein takes first place in the Image Exams Category every year.
135
• X-ray
• Ultrasound
• Ultrasound with Doppler
• Tomography The Boris Berenstein Medicina Diagnóstica Group offers the most complete
and up-to-date diagnostic imaging service, with more than 400 types of
Diagnostics • Resonance
exams within the specialties: X-ray, Magnetic Resonance, Computed
• Bone Densitometry Tomography, Ultrasound, among others.
• Mammography
• Cardiologic Exams
• Endoscopy

136
S W O T
• The products are available • Boris Berenstein • The company's business • New product developed by
through a robust network Diagnostic Center has can boost growth in its the competitor of
of care providers mainly high expose to existing core business, diagnostic labs market
throughout the Brazil and governmental litigations growing in advances, and could be a serious threat
also serve the domestic and legal proceedings driving customer & for company. Competitors
market acting as key with regard to possible operational excellence in having strong foothold in
strength of the company. anticompetitive market the regional presence. The emerging nations may
practices. Also, the new product innovation pose a serious threat for
company has financial helps the company to the company. Such
position and operations capture new untapped factors could affect
could be affected business opportunities company's competitive
materially by adverse position, that further
outcomes. results in reducing
revenue and consequently
affects financial results.

There are no recent developments for Boris Berenstein Diagnostic Center in the Brazil diagnostic labs market.
137
13.8 Clínica da Imagem do Tocantins
13.8.1 Key Facts
Clínica da Imagem do Tocantins
Founded 1977
Corporate Address R. 13 de Maio, 1359 - Centro, Araguaína - TO, 77803-130, Brazil
Telephone +(63) 9 9253-3396
URL www.clinicadaimagemto.com
Location Global

Clínica da Imagem do Tocantins carries more than 45 years of dedication, professionalism, and responsibility in providing a welcoming, humanized,
efficient service and the best cutting-edge technology. The company is equipped with radiology, nuclear medicine, and clinical analysis technology,
assessing the quality of the method through information on equipment, clinical staff, images, and reports. Since the company's inception, the main
objective has been to improve the quality of exams, offering benefits such as reducing mortality and early detection of pathologies. The company is
proud to have four quality seals available from the Brazilian College of Radiology certificate in resonance, mammography, ultrasound, and tomography.

the company is largest reference in diagnostic imaging in the North region and in constant
Clinical • Diagnostics transformation to offer premium care to all its patients. Also, the company is recognized as
a leader in diagnostic imaging assistance in the Northern Region of Brazil.
138
S W O T
• The company is • Diagnostics Labs facing • The company may pursue • Emergence of new players
encompassed in infringement issues with inorganic growth in developed, as well as
diagnostics and services. various medical strategies responsible for developing nations offer a
Additionally, company is companies may result in expanding business. Also, stiff competition for the
also offering a broad litigation that can affect the company main focus company. Also, the pricing
range of products in the the brand image and is on online distribution policies of local players
field of diagnostics labs revenue generation of the channel that helps have the potential to
market. Such company. Such factors strengthen geographic hamper the adoption of
aforementioned factors lead to weaknesses for footprints acting as strong diagnostic labs market for
acts as key strength for the company's overall opportunity for the overall the company.
the company's overall growth and expansion. company's growth/.
business growth.

There are no recent developments for Clínica da Imagem do Tocantins in the Brazil diagnostic labs market.
139
13.9 Hermes Pardini
13.9.1 Key Facts
Hermes Pardini
Founded 1959
Corporate Address Rua Aimores,66 - Funcionarios, Belo Horizonte, Minas Gerais, 30000-000, Brazil
Telephone +55 31 3228-6200
URL www.hermespardini.com
Location Global

Hermes Pardini has complete focus on the customer since its inception. The company owns hospitals, doctors, other laboratories, and patients at the
center. Additionally, there are 67 own units in Belo Horizonte/MG and the metropolitan region and 5 in the city of São Paulo/SP, working 24 hours a
day, seven days a week, to practice Diagnostic Medicine with accuracy, responsibility, quality, and technicalities. Also, Hermes Pardini is the precursor
of the laboratory support market, with around 6 thousand partner laboratories aiming to improve its services based on the understanding of the reality
and needs of end customers.

The company conducting diagnostics test under laboratory tests involves blood count,
• Laboratory Tests blood glucose, creatinine, and ultra-sensitive tsh testing. For quick access testing, the
Diagnostics Services
• Imaging Exams company conducting diagnostic testing involves transvaginal pelvic use, conventional
electrocardiogram, and Rx Thorax Pa Lat.
140
S W O T
• Hermes Pardini seeks to • The rising concerns about • The company conducting • High dependency on
deliver sustainable and safety have some global surveys offering its global supply chains and
profitable growth by negative impact on results employees the ability to production that are
developing and selling of operation and product offer valuable insights complex and subject to
products worldwide that sales. Additionally, the help address potential regulatory requirements
make people's lives rising concerns resulting risk and identify can adversely affect the
healthier by embracing its in safety alerts, opportunities to improve. supply, sourcing, and
sustainability, diversity, governmental Such factors acts as pricing of materials used
equity, and inclusion with investigations, product lucrative opportunity for in the products of the
social responsibility recalls, private claims and the company's overall company acting as a key
strategies across the lawsuits, regulations, growth. threat responsible for the
organization. declining sales, and growth of company.
reputational damage acts
as strong weakness for
the company's overall
growth.
141
Siemens Healthineers announced collaboration with Hermes Pardini for
transforming in-vitro diagnostic care delivery by developing "The Enterprise
Project" in Minas Gerias, Brazil. The Enterprise Project is largest and most
Siemens Healthineers, Hermes Pardini Group to
complex clinical analysis laboratory known to date and is expected to be capable
Apr-2018 Create an Unprecedented Automated Lab Featuring Collaboration
of handling 110 million sample tubes annually upon completion. Additionally, the
the Atellica Solution
Enterprise Project delivers a 3D view of the laboratory configuration, enabling
operators to manage alerts, control instruments, and reagent monitoring
remotely and observe test progression in real time.
142
13.10 Abramed (BP Medicina Diagnostica)
13.10.1 Key Facts
Abramed
Founded 1859
Corporate Address R. Oscar Freire, 379 - 9th floor - Cerqueira César, São Paulo, Brazil
Telephone +(11) 4305-4880
URL www.abramed.com
Location Global

BP Medicina Diagnóstica is the diagnostics unit of BP-The Portuguese Beneficence of São Paulo. The company is a complete and updated diagnostics
and treatment center offering the most diverse modalities of laboratory tests, diagnostic imaging, graphic methods, endoscopy, hemodialysis,
hemodynamics, and other diagnostic specialties. The company performs more than 5 million tests and treatments annually, providing more effective
prevention and more efficient treatments. Additionally, provides valuable knowledge of medicine. Further, in 2020, BP Medicina Diagnostica innovated
for customer-centric approach by taking care of their health with complete safety. Examples include "drive-thru" service for collecting laboratory tests,
including COVID-19. Such an innovatory approach adopted by BP Medicina Diagnostica contributes to customers who faced laboratory results delayed
owing to social isolation required during the COVID-19 pandemic and quickly have the test results in hand to proceed with respective treatments.
143
• Laboratory Tests
• Diagnostic Imaging
Abrmaed Diagnostica offers more than 5
• Graphic Methods million tests and treatments that are
Diagnostic Services • Endoscopy performed annually, providing more
• Hemodialysis effective prevention and more efficient
treatments.
• Hemodynamics
• Other Diagnostic Specialties

144
S W O T
• The company has a wide • Abramed biggest • The company has expand • Many local players are
range of products in its weakness stands as it is its global reach through offering products with
product portfolio that completely dependent on various strategies their brand names. Such
strengthen the position in supply chain network for involving product launch, factors create intense
the global market. Also, the manufacturing and merger, and acquisitions. competition for the overall
the company has strong timely distribution of its Such factor acts as a company to stay firm in
geographic presence products related to standalone factor the competitive
through its various diagnostics. Also, the responsible for overall environment creating a
subsidiaries present supply chain network is market growth during the huge threat for the
globally. Further, it has exposed to various forecast period. company's growth in the
strong brand image in the adverse events that may near future.
market. serve as a weakness for
the company's overall
growth.

There are no recent developments for Abramed in the Brazil diagnostic labs market.
145
14. Appendix
14.1 Glossary of Terms
Table 27. Glossary of Terms, Blood Bank Market
Acronym Expansion
ANVISA Agência Nacional de Vigilância Sanitária
POC Point-of-Care Diagnostics
CAGR Compound annual growth rate
AI Artificial Intelligence
CDC Centers for Disease Control and Prevention
FDA The Food and Drug Administration
GBD United States Burden of Disease
GDP Gross Domestic Product
IoT Internet of Things
PEST Political, Economic, Social, Threats
R&D Research and Development
HRD Homologous Recombination Deficiency
DASA Digital Assisted, Sensibly Augmented
SWOT Strength, Weakness, Opportunity, Threat
WBC White Blood Cells
WHO World Health Organization
146
CMS Centers for Medicare and Medicaid Services
POL Physician Office Laboratory
ECG Electrocardiogram
CVIS Cardiovascular Information System
DALYs Disability Adjusted Life Years
ELISA Enzyme-Linked Immunosorbent Assay
PCR Polymerase Chain Reaction
OOPEs Out-of-Pocket Expenditures
UHS Universal Health System
NCBI National Center of Biotechnology Information
IVD In-Vitro Diagnostics
CT Computed Tomography
Y-O-Y Year-on-Year
147
CONTACT US
If you have any queries about this report or would like further information, please contact us:
United States: +1 646 491 9876
AsiaPacific: +91 20 6727 8686
Email: sales@theinsightpartners.com
DISCLAIMER
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying,
recording or otherwise without the prior permission of the publisher, “The Insight Partners”.
148

Brazil Diagnostic Labs Market: Forecast To 2028 - Covid-19 Impact and Country Analysis

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Brazil Diagnostic Labs Market: Forecast To 2028 - Covid-19 Impact and Country Analysis

Uploaded by

Copyright:

Available Formats

Brazil Diagnostic Labs Market

Forecast to 2028 – Covid-19 Impact and Country Analysis

1.2 The Insight Partners Research Report Guidance.............................................................................................................................................. 20

1.3 Market Segmentation ......................................................................................................................................................................................... 22

1.3.1 Diagnostic Labs Market – By Lab Type ............................................................................................................................................. 23

1.3.2 Diagnostic Labs Market – By Testing Services ................................................................................................................................. 23

1.3.3 Diagnostic Labs Market – By Revenue Source................................................................................................................................. 24

1.3.4 Diagnostic Labs Market – By Geography .......................................................................................................................................... 24

2. Diagnostic Labs Market – Key Takeaways .................................................................................................................... 25

3.2 Secondary Research ........................................................................................................................................................................................... 29

3.3 Primary Research ................................................................................................................................................................................................ 30

4. Diagnostic Labs Market – Market Landscape ............................................................................................................... 31

4.2 PEST Analysis ...................................................................................................................................................................................................... 31

4.2.1 Brazil – PEST Analysis ........................................................................................................................................................................ 31

5.1.1 Rising Prevalence of Ageing-Related Diseases and Chronic Diseases ........................................................................................... 32

5.1.2 Growing Use of Point-of-Care Diagnostic Products ........................................................................................................................... 32

5.2 Market Restraints ............................................................................................................................................................................................... 33

5.3 Market Opportunities .......................................................................................................................................................................................... 33

5.3.1 Increasing Number of Strategic Collaborations and Partnerships .................................................................................................. 33

5.3.2 For instance: ....................................................................................................................................................................................... 34

5.4 Future Trends ...................................................................................................................................................................................................... 35

5.5 Impact Analysis ................................................................................................................................................................................................... 36

6. Diagnostic Labs Market – Brazil Analysis ..................................................................................................................... 37

6.3 List of Distributors in Brazil-Diagnostic Labs Market........................................................................................................................................ 38

6.4 Company Analysis ............................................................................................................................................................................................... 39

6.4.1 Market Positioning of Key Players ..................................................................................................................................................... 39

6.4.2 Comparative Company Analysis ........................................................................................................................................................ 40

6.4.4 Performance of Key Players ............................................................................................................................................................... 43

6.4.4.1 Dasa Labs ...................................................................................................................................................................... 43

6.4.4.2 Grupo Fleury .................................................................................................................................................................. 44

6.5 Market Share Analysis of Brazil Diagnostic Labs Market ................................................................................................................................. 45

7.3 Hospital-based Labs ........................................................................................................................................................................................... 47

7.3.1 Overview .............................................................................................................................................................................................. 47

7.4 Single/Independent Laboratories ...................................................................................................................................................................... 48

7.4.1 Overview .............................................................................................................................................................................................. 48

7.5 Physician Office Labs (POL) ................................................................................................................................................................................ 49

7.5.1 Overview .............................................................................................................................................................................................. 49

7.6 Others .................................................................................................................................................................................................................. 50

7.6.1 Overview .............................................................................................................................................................................................. 50

8.3 Physiological Function Testing ........................................................................................................................................................................... 52

8.3.1 Overview .............................................................................................................................................................................................. 52

8.3.3 Endoscopy Market .............................................................................................................................................................................. 53

8.3.3.1 Overview ......................................................................................................................................................................... 53

8.3.4 X-Ray Market ....................................................................................................................................................................................... 54

8.3.4.1 Overview ......................................................................................................................................................................... 54

8.3.5 CT Market ............................................................................................................................................................................................ 55

8.3.5.1 Overview ......................................................................................................................................................................... 55

8.3.6 ECG Market ......................................................................................................................................................................................... 56

8.3.6.1 Overview ......................................................................................................................................................................... 56

8.3.7.1 Overview ......................................................................................................................................................................... 57

8.3.8 Echo Market ........................................................................................................................................................................................ 58

8.3.8.1 Overview ......................................................................................................................................................................... 58

8.3.9 Others .................................................................................................................................................................................................. 59

8.3.9.1 Overview ......................................................................................................................................................................... 59

8.4 General and Clinical Testing .............................................................................................................................................................................. 60

8.4.1 Overview .............................................................................................................................................................................................. 60

8.5 COVID-19 Testing ................................................................................................................................................................................................ 61

8.5.1 Overview .............................................................................................................................................................................................. 61

8.6 Esoteric Testing ................................................................................................................................................................................................... 62

8.6.1 Overview .............................................................................................................................................................................................. 62

8.7 Specialized Testing ............................................................................................................................................................................................. 63

8.8 Noninvasive Prenatal Testing ............................................................................................................................................................................. 64